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ii 
 
ith an ever increasing incidence of type 2 diabetes in the New Zealand population, 
continual assessment must be made to ensure the ongoing evaluation of treatment 
options to ensure patient care is not compromised. Previous research has shown higher prevalence 
of Vitamin B12 deficiency in patients with type 2 Diabetes Mellitus who have had long term 
metformin treatment. An investigation into patients attending secondary care clinics at the Diabetes 
Clinic at Wellington Regional Hospital as well as primary health care patients has explored the 
prevalence of this interaction in the New Zealand population as well as assessed the factors that may 
contributed to such an effect. It was found that there is a high prevalence of decreased serum 
Vitamin B12 level in patients with type 2 Diabetes exposed to metformin treatment. Factors such as 
age and ethnicity were seen to be key predictors of this interaction and have shown a unique view of 
how the population of New Zealand may be affected.  
Treatment of decreased serum Vitamin B12 levels was seen to be effective through both 
sublingual and intramuscular methods with variations in both short and long term effects. The use 
of sublingual treatment administration of Vitamin B12 supplementation is unique in the scope of 
metformin induced Vitamin B12 deficiency and has shown potential to be a therapeutic route for 
patients affected by such an interactions. Current views on the interaction between metformin and 
serum Vitamin B12 levels are currently under debate in regards to physiological relevance and 
clinical outcomes. This paper provides a first look at the effect of this interaction in a New Zealand 
population and evaluates treatment options for such. Furthermore a proposal is made for an 
alternate mechanism of metformin action on Vitamin B12 levels which may aid understanding of 
observations made in both in this paper and previous studies.  
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2.0 Introduction 
2.1 – Diabetes 
 
The number of people with type 2 diabetes is expected to double between the years 2000 and 
2030(J. E. Shaw, Sicree, & Zimmet, 2010). A combination of population growth, population aging, 
and increased rates of obesity as urbanization and commercialization sweeps the globe has increased 
the incidence of diabetes in recent years. It is estimated that some 382 million people globally now 
have some form of diabetes, of which approximately 46% of cases are undiagnosed 
(InternationalDiabetesFederation, 2013). This steep increase in incidence has led to a high mortality 
in many countries, up to 76% of all deaths under the age of 60 in some African countries as well as a 
large financial burden on health care systems; costing the United States of America $245 billion 
dollars alone in the last year and an estimated £1 million each and every hour in the UK (Diabetes 
UK, October 2008). The current trend of incidence suggests that the number of patients suffering 
from diabetes in the year 2035 will be above 590 million worldwide with developing countries 
increasing in incidence at higher rates than those in most developed countries 
(InternationalDiabetesFederation, 2013).  
 
Globally type 2 diabetes makes up more than 90% of confirmed diabetes cases diagnosed (Zimmet, 
Alberti, & Shaw, 2001). While traditionally the disease was not seen in younger patients, this has 
been observed to be a changing trend. Increased rates of childhood obesity are resulting in 
increasing incidence of type 2 diabetes in young people (Farsani, van der Aa, van der Vorst, Knibbe, 
& de Boer, 2013). High levels of heritability (Rathmann, Scheidt-Nave, Roden, & Herder, 2013) 
coupled with a lack of patient education has led to families and communities being stricken by the 
epidemic. The ease of access to high sugar and fat containing low cost food has fuelled this rise in 
many developed as well as developing countries (Hu, 2013). 
 
Diabetes surveillance in New Zealand has been greatly strengthened by the development and 
utilisation of the Virtual Diabetes Register. The Virtual Diabetes Register (VDR) allows for the 
pooling of information through various health system levels to form a comprehensive over view of 
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the prevalence across the country. The VDR filters information gathered from hospital admissions, 
outpatient services, pharmaceutical dispensaries, pathology tests, and  primary health organization 
enrolment data to allow analysis on a nationwide level. Figures released in December 2012 
identified a total of 225,731 patients who had been identified with diabetes by the VDR . Of this 
entire population there are increased numbers of diabetes cases within certain ethnic groups 
suggesting increased risk rates with people of Pacific identity having a prevalence of type 2 diabetes 
of up to 10% in adults (A Potrait of Health: Key results of the 2006/2007 New Zealand Health Survey., 
2008). According to Ministry of Health data the incidence of diabetes in New Zealand is still 
increasing. Current estimates of prevalence of diabetes in New Zealand were up to 7.0% in 
2008/2009 (Coppell et al., 2013) with a pre-diabetes prevalence of 25.5%. It is believed that part 
of the recent increase in incidence is a result of increased detection. Diagnosis has been seen to 
increase the ratio of diagnosed to undiagnosed patients with specific improvements in Maori 
populations, much improvement is still needed with some populations reporting an undiagnosed 
rate of 6.4% of the entire population (Coppell et al., 2013). The prevalence of pre-diabetes in the 
population with high risk groups reaching 35.8%, in obese men, is of great concern for the 
potential further explosion of diabetes. A large pre-diabetic population coupled with an earlier 
onset of diabetes type 2 in youth populations is certain to lead to increased burden on the health 
sector in the coming years and requires constant and vigilant monitoring combined with proactive 
and preventative care strategies.  
 
 
The disease state of diabetes highlights the need for constant homeostasis within the body and the 
damage that can result if these checks and balances are not constantly maintained at optimal levels. 
Glucose is derived from the digestion of food containing carbohydrate. As the glucose is absorbed 
into the blood stream the pancreas monitors the blood glucose level to ensure that it does not 
become too high (after a meal) or too low (during a fasting period). This function is predominantly 
carried out through the secretion of two opposing hormones, insulin and glucagon. As glucose 
levels rise as a result of food digestion it enters the β cells in the pancreatic islets. The influx of 
glucose signals the β cells to release the hormone insulin into the blood stream which is then 
transported to cells throughout the body and promoting cellular uptake of glucose. Muscle cells use 
the glucose for energy in biochemical reactions. Other target sites such as in the liver also result in 
further downstream mechanisms resulting from insulin interaction. Insulin uptake by the liver 
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results in the increased absorption of glucose from the blood and conversion of this glucose into 
glycogen which acts as an energy storage molecule. During fasting periods when blood glucose 
levels are low, the pancreas releases glucagon via α cells. This hormone enters the blood stream and 
acts on target cells in the liver, this signals the liver cells to break glycogen down into glucose and 
the molecules are released back into the blood to maintain a supply of glucose to organs that require 
a constant supply such as the brain.  
  
Diabetes is the result of the inability of the body to maintain blood glucose levels at optimal 
levels. Glucose derived from food digestion cannot be absorbed by target cells and continues to rise 
as continual glucose is absorbed from the diet. The kidney has limited ability to reabsorb filtered 
glucose, such that above a plasma concentration of approximately 10mmol/L, there is loss of 
glucose in the urine. This results in an osmotic gradient which leads to increased water loss and 
polyuria. Higher urine production leads to thirst as excessive amounts of water are expelled from 
the body. The excess glucose in the urine also increases the risk of urinary infections as bacteria are 
supplied with an ample source of energy in which to thrive. High circulating glucose concentrations 
also results in other symptoms of uncontrolled diabetes such as blurred vision as the osmotic effect 
causes fluid shifts from the lens in the eye distorting its shape. High blood glucose also impairs the 
function of white blood cells and leads to slow healing of soft tissue infections. As the body is not 
able to derive energy from the circulating glucose molecules, patients with untreated type 1 
diabetes can often feel tired or lethargic as their body attempts to find energy sources to maintain 
body functions. One way the body does this is by breaking down fat stores in the body resulting in 
weight loss. 
 
Type 1 diabetes is characterised by the autoimmune destruction of the β cells in the pancreas which 
are responsible for the synthesis and release of insulin (Battaglia, 2014).  In type 2 diabetes the β 
cells are still initially functional and still release insulin. However the insulin responsive tissues such 
as liver, skeletal muscle and adipose, do not respond as efficiently to insulin to promote glucose 
uptake into cells. In addition, the beta cell function declines and progressively generates less insulin. 
One proposed mechanism that leads to these changes is excess deposition of fat in the non-adipose 
tissues, particularly liver and muscle. This results in impairment of insulin signalling and glucose 
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uptake, but also reduced switching off of glycogen breakdown in the liver and release of glucose 
into the circulation. The pancreas eventually fails to keep up with the required insulin production 
and loses function itself. Both of type 1 and type 2 diabetes result in excess blood glucose levels and 
the effects described above.  
The increase of glucose concentrations in the blood if not treated can lead to both microvascular 
and macrovascular complications. Damage to the blood capillaries through microangiopathy can 
lead to the development of many complications. Endothelial cells lining capillaries are constantly 
exposed to increased glucose concentrations and increased glucose uptake results in the formation 
of excess glycoproteins on the cell surface. This leads to the thickening and weakening of the 
basement membrane. This process has been attributed to the development of cardiomyopathy, 
nephropathy, neuropathy and retinopathy. These impairments can lead to visual symptoms, chronic 
kidney disease, and commonly the loss of sensation in the peripheral nervous system (Nathan & 
Grp, 2014). Additionally, some research in type 1 diabetes suggests that the autoimmune response, 
responsible for the pancreatic destruction, may also contribute to some of these microvascular 
complications (Ichinose, Kawasaki, & Eguchi, 2007).  
 Vascular abnormalities are not limited to capillaries; macrovascular complications of 
diabetes are a common cause of fatality in patients with diabetes.  The development of 
atherosclerosis, subsequent plaque rupture and overlying clot formations in the large vessels of the 
body increase the likelihood of ischemia and subsequent cardiovascular events such as myocardial 
infarction, stroke or peripheral vascular disease. Patients with type 2 diabetes may be more 
susceptible to macrovascular disease because of additional risk from hypertension and dyslipidaemia 
associated with obesity. Intensive treatment of glucose levels in diabetes, aiming for near-normal 
glucose concentrations has seen reduction in both micro and macrovascular complications and 
improve outcomes for those with diabetes (Rensing et al., 2011; Rosenson, Fioretto, & Dodson, 
2011).  
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The evidence for the benefits of good glycaemic control are numerous and convincing. Many large 
scale studies have evaluated the many facets of diabetes management and pathogenesis in order to 
form a comprehensive picture of the treatment effects. The United Kingdom Prospective Diabetes 
Study (UKPDS) is one such study that has shown significant improvements in health following a 
strict glycaemic control program. The randomized multicentre intervention trial studied the effects 
of treatment such as diet, insulin and metformin on complications of diabetes, associated morbidity 
and mortality. The study has shown that intensive glycaemic control resulted in decreases of 
diabetic microvascular complications (Mooradian & Chehade, 2000; R. C. Turner & Holman, 
1996; Wright, Cull, Macleod, Holman, & Grp, 2006). While initial results from the study showed 
only modest improvements in cardiovascular disease risk, this was seen to be more significant 
following analysis of metformin treatment.  
By the three month time period the patients randomized to metformin treatment had 
shown reductions in fasting blood glucose, similar to insulin and sulfonylureas, but also showed 
improvements in fasting plasma insulin and no weight gain. Furthermore the number of 
hypoglycaemic episodes was much lower than those in sulphonylureas or insulin therapy. Evaluation 
of diabetes related complications showed metformin treatment had a lower risk of any diabetes-
related endpoint, diabetes related-death, all-cause mortality,  myocardial infarction (39%) and all 
macrovascular diseases when compared to diet alone treatment. UKPDS showed that metformin is 
as effective as sulfonylureas and insulin in glycaemic control, but without weight gain and a lower 
risk of hypoglycaemia (Group, 1995).  
 
 The Diabetes Control and Complications Trial (DCCT) was a large scale assessment of the effects 
of a tight glycaemic management program on the complications of type 1 diabetes (Nathan & Grp, 
2014). The study aimed to compare intensive treatment of patients with type 1 diabetes in order to 
maintain a median HbA1c of 7%, to conventional treatment of patients with maintenance of HbA1c 
of 9%.  The results from DCCT provided evidence for the benefits of aiming for near normal 
glycaemic control. However the trade-off of tight glycaemic control was an increased rate of 
hypoglycaemia and weight gain. The results have shown that intervention with strictly decreased 
glucose level results in improvements in all areas of microvascular and cardiovascular complications 
of type 1 diabetes. Presence of early stage microvascular complications were reduced by 35-76% in 
patients exposed to intensive glycaemic control. Major beneficial effects of intensive control were 
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seen in, retinopathy, nephropathy, and neuropathy. Measurements of atherosclerosis have revealed 
less atherosclerosis in the intensive treatment group, corresponding to decreases in clinical 
presentations of fatal and nonfatal myocardial infarctions and stroke, a reduction of 58% in 
cardiovascular related disease events after 18 years of follow-up from the beginning of the DCCT. 
However the observational study, The Epidemiology of Diabetes Interventions and Complications 
(EDIC) which was used concurrently with the DCCT, has shown that the differences in the Hba1c 
of each of the treatment groups deteriorated in the later periods of patient monitoring. This 
phenomenon was labelled “metabolic memory” and was seen to effect all microvascular 
complications of diabetes and relate to glycation of proteins (Monnier et al., 1999).  
 
American Diabetes Association (ADA) guidelines for the management of type 2 diabetes state the 
initial pharmacological intervention suggested is in the form of metformin ("Executive summary: 
Standards of medical care in diabetes--2013," 2013). If noninsulin monotherapy does not alleviate 
the increased glucose levels in patients after 3 months then a second agent such as a glucagon-like 
peptide 1 receptor agonist is indicated. The initiation of insulin is required in markedly 
symptomatic patients with newly diagnosed type 2 diabetes or as an outcome of disease progression 
beyond the control of oral agents.  
This front line role of metformin is similar in many guidelines set by healthcare agencies. 
New Zealand and Australian standards both recommend commencement of metformin treatment if 
no contradictions are present and inadequate improvements due from diet or lifestyle changes. 
 
 
  
 
7 
 
2.2 – metformin 
 
Metformin has been used to combat high blood glucose since middle age Europe where its active 
ingredient was extracted from the French lilac plant. It belongs to the biguanide class of oral 
antidiabetic drugs. However its physiological benefits stretch further than its antihyperglycaemic 
properties. A range of additional affects such as improvements in endothelial function, haemostasis 
and oxidative stress, insulin resistance, lipid profiles, and fat redistribution accompany the primary 
glycaemic function of metformin (Aguayo Rojas & Gomes, 2013). While the biochemical mode of 
action of metformin is still not completely understood, its utilization is vast and it is still considered 
to be the first-line oral antidiabetic treatment for patients with type 2 diabetes (Bouchoucha, Uzzan, 
& Cohen, 2011).   
 
The action of metformin on glucose metabolism is dependent on the presence of insulin. The main 
site of metformin action is thought to be in the liver where the drug suppresses glucose production. 
It promotes glucose uptake by tissues via the glucose transporters, and inhibits hepatic 
gluconeogenesis (Bouchoucha et al., 2011). It is thought that the main mode of action for the 
antihyperglycaemic property of metformin occurs via the activation of adenosine monophosphate 
(AMP) – activated protein kinase (AMPK). AMPK is activated in the brain by metabolic stresses 
that inhibit ATP production such as ischemia, hypoxia, glucose deprivation, metabolic inhibitors 
(such as metformin), as well as catabolic and ATP consuming processes. 
More in-depth analysis of biochemical regulations affected by metformin has shown that these 
effects are mediated by the activation of an upstream kinase, liver kinase B1 (LKB-1), this in turn 
regulates the downstream kinase adenosine monophosphatase co-activator. This allows the 
transduction of regulated CREB protein 2 (TORC2), resulting in its inactivation and thus the down 
regulation of transcriptional events that promote synthesis of gluconeogenic enzymes.  Inhibition of 
mitochondrial respiration has also been proposed to contribute to the reduction of gluconeogenesis 
as it directly  reduces the energy supply required for this process (R. J. Shaw et al., 2005).  
Further to its kinase interactions there are numerous additional actions of metformin such as 
alterations to small intestine glucose metabolism and small bowel absorption that alter the 
absorption profiles of some vitamins (Qureshi, Ainsworth, & Winocour, 2011).  
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Metformin has consistently shown improvements not only in glycaemic control but also in 
cardiovascular management (Rojas & Gomes, 2013). Evidence for the ongoing utilization of 
metformin as a front line anti-diabetic drug in both obese and non-obese patients is strongly 
supported (Ito et al., 2010). The progression of type 2 diabetes often results in an increased dose of 
drug being required at later disease stages, however even small dosages can improve Hba1c and 
diabetic outcomes.  
 
The most common side effects of metformin treatment are gastrointestinal – including 
nausea, vomiting and diarrhoea. These usually minor side-effects are observed in approximately 
30% of patients, and lead to treatment discontinuation in 5% of patients (Rojas & Gomes, 2013). 
The gastrointestinal side effects are commonly addressed by using slow titration of dosages to wean 
patients onto the drug.  Commonly, but not universally, people become more tolerant to these side 
effects over time.  There have also been associations with the potentially serious and sometimes 
fatal side-effect of lactic acidosis, although there is much controversy over the real risk conferred by 
metformin. 
 
Further studies into alternate applications of metformin treatment and observation of 
additional physiological outcomes of the use of the drug have resulted in advantageous outcomes for 
reducing incidence and mortality in patients suffering from a variety of carcinomas (Zhang, Li, Tan, 
Chen, & Wang, 2013; Riedmaier, Fisel, Nies, Schaeffeler, & Schwab, 2013). Studies into the effect 
of metformin in cancer patients has suggested that the glycaemic control of metformin, which 
involves the absorption of glucose by tissue such as large muscle, may aid in the reduction of 
tumours as it limits the amount of sugar available to the uncontrolled proliferating cells which are 
characteristic of carcinoma growth. Investigation has suggested that the use of metformin can 
directly inhibit cancer cells by initiating the LKB1/AMPK/mTOR axis which works to regulate 
energy metabolism as well as protein synthesis within the cells. A meta-analysis identified four 
different cancer types which showed marked improvement in incidence and mortality if patients had 
been treated with metformin. The risk of developing liver, pancreatic, colorectal and breast cancers 
were reduced by 78%, 46%, 23% and 6% respectively. Mortality was reduced in liver cancer to 
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0.23 and breast cancer reduced to 0.63 (Zhang, Li, Tan, Chen, & Wang, 2013). metformin has also 
been seen to provide decreased likelihood of hepatocellular carcinoma development in patients 
suffering from chronic hepatitis C virus(Harris & Smith, 2013). 
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2.3 – Vitamin B12 
 
Vitamin B12, also referred to as cobalamin (Cbl), is one of eight B group vitamins and is thought to 
play a large role in the formation of blood as well as key roles in brain and nerve function. The 
vitamin has several different structural forms depending on method of synthesis and processing. 
Hydroxocobalamin is the most commonly formed structure synthesized by bacteria; it is also the 
form in which the compound is found in the intramuscular injection commonly used to treat 
deficiencies. The extraction of hydroxocobalamin in pharmacological manufacturing can result in 
the compound being converted to cyanocobalamin through the change of a ligand group. This form 
of the vitamin is considered semi-synthetic and is commonly used due to its low cost and high 
stability. Conversion of both hydroxocobalamin and cyanocobalamin to the human physiological 
form adenosylcobalamin and methylcobalamin occurs in the body in order for bioavailability of the 
vitamin to take place.  
The key structural changes that occur between the different forms of Vitamin B12 occur in 
the upper axial ligand (β-axial ligand). Derivatives of physiological importance, adenosylcobalamin 
(co-enzyme B12) and methylcobalamin have a 5-deoxy-5-adenosine or methyl group as the upper 
axial ligand respectively. Cyanocobalamin contains a cyanide group in the β-axial ligand (Takahashi-
Iniguez, Garcia-Hernandez, Arreguin-Espinosa, & Flores, 2012).  
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Figure 2.3.1 – Chemical structure of cobalamin, R group represents either, 5’-deoxyadenosyl, 
Me, OH, or CN depending on form of cobalamin 
 
 
 
 
 
 
 
 
 
 
 
Vitamin B12 is produced by bacteria and fungi. While there are certain bacteria in the human large 
bowel which produce the vitamin, this form is not absorbed and therefore humans need to obtain 
the vitamin through dietary sources. The sources which are highest in concentration of Vitamin B12 
are animal products such as meat and eggs with varying levels depending on source. Meat sources 
such as shellfish and beef have the highest concentration of Vitamin B12 with upwards of 70 
micrograms per serving, about 1,000 % of the daily value recommended by the United States Food 
and Drug Administration (FDA). Other sources such as fish and fortified cereals have much lower 
levels of Vitamin B12 (between 2 and 6 micrograms per serving) whilst sources such as milk and 
eggs have lower range levels (1.2 and 0.6 micrograms per serving respectively) (Dietary reference 
intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline, 
1998; Montville et al., 2013). This creates a problem for people who adhere to a strict vegetarian 
diet and supplementation via intramuscular injection and/or oral supplements may be required. 
Certain algae and seaweeds have been proposed as sources of Vitamin B12 however the 
bioavailability of the vitamin from these sources is still disputed (Kwak, Park, & Cho, 2012) . In a 
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western country the average non-vegetarian diet includes around 5 to 8 micrograms of cobalamin 
daily. This is higher than the recommended daily allowance of 2.4 micrograms for adults, although 
this is higher in pregnant or lactating women (2.6 and 2.8 micrograms respectively). A strict 
vegetarian however may consume only 0.5 micrograms a day and therefore be at the risk of 
deficiency.  Due to our large natural stores of the vitamin it may take an extended period of time 
for a deficiency to develop however. The mode of absorption, trafficking and metabolic exchange 
that take place with Vitamin B12 highlight the rarity and essential nature of the compound (Gueant 
& Alpers, 2013). Although the compound is seen to be carefully monitored throughout its 
metabolic pathway through the body system, it has been identified as being involved in only two 
important metabolic processes in the human body. These include the metabolism of Homocysteine 
(Hcy) and Methylmalonyl-CoA (MMA). In a broader sense, B12 is involved in the formation of red 
blood cells, to sustain function in the nervous system, DNA synthesis and cell proliferation. 
 
The journey of Vitamin B12 from intake to absorption follows the binding of the compound 
to several different protein structures and the involvement of numerous digestive enzymes. Vitamin 
B12 initially binds to haptocorrin following proteolytic digestion by pepsin in the low pH 
environment of the stomach (Gherasim, Lofgren, & Banerjee, 2013). Haptocorrin are Vitamin B12 
binding proteins that are produced in the salivary glands; however the actual binding does not occur 
until pepsin frees the vitamin from the proteins in the food. The Vitamin B12 – haptocorrin 
complex is referred to as “holo-R-protein” which remains bound until degradation by pancreatic 
proteases released into the upper small bowel. This allows the Vitamin B12 to be bound to gastric 
intrinsic factor (GIF), forming cobalamin-IF. This new complex travels to the distal ileum where 
recognition of its receptor which are selective for cobalamin-IF and not holo-R-protein allows the 
uptake of the vitamin complex (Alpers & Russell-Jones, 2013).  The receptors are located on the 
enterocytes in the ileum thus uptake of Vitamin B12 is through these cells. While the exact 
processes that occur within these enterocytes are not fully understood, the cobalamin appears 
bound to transcobalamin II (TCII) in the portal blood. The TCII-cobalamin complex is rapidly 
cleared due to specific binding sites on numerous cells. Internalization of TCII-cobalamin leads to 
dissociation of the complex and conversion of the cobalamin into its physiologically active forms. 
Both transcobalamin and intrinsic factor bind cobalamin in a base-on conformation, however the 
binding mode for haptocorrin depends on the lower axial ligand, this allows for the clearance of 
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analogous to Vitamin B12 from the blood through selective binding to the haptocorrin transport 
protein (Gherasim et al., 2013).  
 
The two forms of cobalamin that are found in the human body both have differing 
physiological roles. Adenosylcobalamin acts as a coenzyme of methylmaloyl-CoA mutase, the main 
function of this protein is the conversion of methymalonyl-CoA to succinyl-CoA. Methylcobalamin 
works as a co-enzyme of methionine synthetase which catalyses the movement of the methyl group 
of the cobalamin molecule to homocysteine thus forming methionine, methylcobalamin is 
regenerated by further methyl group transfer. Methionine undergoes further biochemical 
processing to form adenosyl-methionine, a methyl group donator responsible for the methylation of 
many proteins, neurotransmitters and nucleic acids (Gherasim et al., 2013). The metabolism of 
methionin synthase requires a balance of carbon molecules which can lead either towards synthesis 
of DNA and RNA or the methylation of substrate compounds by S-adenosylmethionine (SAM). The 
role of Cbl in this function may therefore alter some epigenetic properties of an individual through 
specific methylation of DNA, RNA, histone and gene expression which may result in a variety of 
physiological differences (Gnimpieba, Eveillard, Gueant, & Chango, 2011).  
 
Clinical presentations of Vitamin B12 deficiency are difficult to identify as being a unique 
symptom of the condition. One of the most common presentations is a feeling of fatigue or “general 
tiredness”; this relates to the role that Vitamin B12 plays in the regulation of sleep patterns. Further 
long term presentations may include neuropathy of the feet as well as (in very deficient cases) the 
development of anaemia. A key problem area in the identification of Vitamin B12 deficiency is the 
over lapping symptomatic expressions with diabetes. Unexplained fatigue may be attributed to low 
sugar levels as a result of medication or alterations in diet or eating habits and therefore may be 
misinterpreted as other problems. Neuropathy as a result of Vitamin B12 deficiency is particularly 
difficult to identify as it mimics that of diabetic neuropathy and can take a long period of time to 
develop. The currently used biochemical markers for diagnosis of Vitamin B12 deficiency are under 
much debate. The traditional serum Vitamin B12 assessment has been suggested to not be sufficient 
in predicting the presence of Vitamin B12 deficiency (Obeid et al., 2013). The current use of serum 
Vitamin B12 level relies on several different range points for Vitamin B12 status. Serum Vitamin 
B12 level under 148 pmol/L are said to be deficient, low/borderline levels are interpreted from 
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levels between 148-220 pmol/L (Mazokopakis & Starakis, 2012). Normal ranges of Vitamin B12 
serum range from 220- 800 pmol/L, levels that exceed this are rarely suspicious in cause, although 
excessive B12 serum may be a marker of myloproliferative disorders. Analysis of biochemical 
markers of methylmalonic acid (MMA) and total homocysteine (tHcy) are said to be more definitive 
at obtaining a correct diagnosis of deficiency with levels >0.28 µmol/L and >15 µmol/L 
respectively being seen as elevated levels and markers of cobalamin deficiency however the cost of 
such assessments is often a barrier (Mazokopakis & Starakis, 2012). 
 
The development of Vitamin B12 deficiency can be triggered by numerous different 
pathways and identification of the causative source of deficiency is crucial to treatment 
administration. Some factors that may lead to eventual deficiency in Vitamin B12 include; gastric 
abnormalities (pernicious anaemia, bariatric surgery etc.), small bowel disease, diet (strict 
vegetarian, vegan), agents that block absorption (neomycin, metformin etc.), impaired utilization 
(congenital transcobalamin II deficiency), and biological competition (bacterial overgrowth etc.) 
(Mazokopakis & Starakis, 2012). While the body usually has a massive store of Vitamin B12 
(≈2500μg) this store can be slowly depleted via any of the above avenues leading to either a 
decreased or deficient state.  
 
Developments of megaloblastic changes have been observed in Vitamin B12 deficient 
environments, however the mechanism for this is not precisely known. Due to the disruption of 
DNA synthesis proliferating cells have been observed in cell cycle arrest in epithelial, peripheral 
blood, and most strikingly in bone marrow cells as a result of Vitamin B12 deficiency. An increase 
in mean corpuscular volume is seen to be the earliest sign of megaloblastosis followed by 
irregularities in the cell shape (Briani et al., 2013).  
 
Vitamin B12 plays a crucial role in the nervous system where it acts as a coenzyme for 
methyl malonyl-CoA mutase reaction, a required step in myelin synthesis. Loss of myelin formation 
can lead to several central and peripheral nervous system pathogenic states such as neuropathy, 
neuropsychiatric abnormalities, myelopathy and possible optic nerve atrophy. The development of 
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neuropathy due to Vitamin B12 deficiency usually begins with sensory impairment in the lower 
limbs. This is commonly seen to correspond with a loss of vibratory sensation, diminished 
proprioception and loss of cutaneous sensation (Senol, Sonmez, Ozdag, & Saracoglu, 2008). 
Neuropsychiatric syndromes associated with Vitamin B12 deficiency include chronic fatigue 
syndrome (Dommisse, 1991), cognitive impairment and depression (Kibirige, Wekesa, Kaddu-
Mukasa, & Waiswa, 2013). 
 
2.4 – metformin induced Vitamin B12 deficiency 
 
The association between metformin treatment and impaired Vitamin B12 status dates back to the 
1970s when the interaction was first proposed (Stowers & Smith, 1971), and estimates of 
prevalence were stated to be close to 30%. Since then the prevalence of metformin associated 
Vitamin B12 deficiency has been reported in many different studies, however the ranges of 
incidence in such populations vary by a large amount. While many studies estimate the rate of 
prevalence to be around 10-20% of treated patients (Calvo Romero & Ramiro Lozano, 2012; 
Leung et al., 2010), other studies have reported levels as low as 5% of treated patients (Reinstatler, 
Qi, Williamson, Garn, & Oakley, 2012) and levels higher than 30% (Nervo et al., 2011). Data 
available in New Zealand in regards to Vitamin B12 deficiency is not metformin specific but rates in 
elderly patients (aged 65 and above) suggest that acquired Vitamin B12 deficiency could be as high 
as 35% (Green, Venn, Skeaff, & Williams, 2005). As there are multiple factors affecting the risk of 
acquiring the deficiency it is imperative to correctly identify the key influences in attempt to 
minimize a compounding effect.  
 
The mechanism for metformin induced Vitamin B12 deficiency is still to be definitively 
deduced. Some of the earliest studies to suggest the relationship were published in the 1970’s 
(Stowers & Smith, 1971; Tomkin, 1973), with data from over 100 patients being compiled into a 
report that highlighted not only the significance of duration of therapy required to lower the 
Vitamin B12 levels, but also suggested a link between therapeutic dose and overall decrease in the 
vitamin level.  
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Stowers et al in the British Medical Journal in 1971 said:  
“We would like to support the recommendation of Dr. Tomkin and others that all patients on long-term 
therapy with metformin should have an annual estimation of serum vitamin B12, for it is otherwise quite easy to 
miss cases of classical macro cytic anaemia and/or signs of subacute degeneration of the cord” (Stowers & Smith, 
1971) 
The current evidence supports a mechanism in which metformin interaction is isolated to 
calcium channel interactions and an impairment of calcium-dependent membrane activity in the 
ileum (Bauman, Shaw, Jayatilleke, Spungen, & Herbert, 2000) which leads to malabsorption of 
Vitamin B12 bound to intrinsic factors. Studies of the association of metformin and Vitamin B12 
effect have yielded numerous related findings (Reinstatler et al., 2012), as well as many conflicting 
views of mechanisms. A measurable reduction in Vitamin B12 levels can occur as quickly as 3-4 
months after the initiation of the metformin therapy (Bauman et al., 2000), while symptomatic 
deficiency may take as long as 5 -10 years to manifest. Many papers agree on the prevalence of 
lowered B12 levels, reported at between 10 – 20% of patients taking metformin (Calvo Romero & 
Ramiro Lozano, 2012; Leung et al., 2010; Liu, Dai, & Jean, 2006; Mazokopakis & Starakis, 2012). 
However there have been several theories into the exact mode of this malabsorption (Musarrat, 
Kalathil, & Varughese, 2008; Nervo et al., 2011). 
 
Due to the variety of pathogenic causes for a deficiency in Vitamin B12 there is no best fit 
mode of treatment for the deficiency. The most common method for treatment of Vitamin B12 
deficiency is the use of intramuscular Hydroxocobalamin injections which are used in a loading 
regimen followed by a maintenance administration for long term treatment (Mazokopakis & 
Starakis, 2012). However there is a requirement for a less invasive and clinically reliant 
administration of treatment in order to address the large number of patients requiring 
supplementation. The investigation into efficacy of oral and sublingual routes of medication has 
resulted in comparable treatment success to that of the parenteral route for some cases, while 
others have shown insufficient corrections in serum Vitamin B12 level (Reinstatler et al., 2012). 
Due to the proposed mechanism of interaction of metformin on absorption of Vitamin B12 the use 
of sublingual supplementation has been gaining favour. Sublingual treatment has been shown to be 
just as effective as oral doses in patients not being treated with metformin (Delpre, Stark, & Niv, 
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1999; Sharabi, Cohen, Sulkes, & Garty, 2003; Yazaki, Chow, & Mattie, 2006) on both serum 
Vitamin B12 level as well as biomarkers of Vitamin B12 functionality. With the current evidence of 
Vitamin B12 malabsorption occurring at the intrinsic factor level (Bauman et al., 2000) it is thought 
that the use of sublingual Vitamin B12 supplementation should be more effective than oral 
administration in patients being treated with metformin; there is no current literature that has 
directly assessed this however. Using studies focused on patients following gastric bypass surgery as 
models for malabsorption of Vitamin B12 is has been seen that intramuscular injections are more 
effective in treatment than oral routes, however again the information on the sublingual route is not 
available.  (Majumder, Soriano, Cruz, & Dasanu, 2013; Shakeri-Leidenmuhler et al., 2013).  
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2.5 – Previous Research 
 
Metformin associated serum Vitamin B12 deficiency has been evaluated thoroughly and the 
association between the two is well documented, however the mechanisms of interaction and 
potential clinical outcomes of such are still in dispute. Evidence has been given to support the 
theory that the metformin interaction is isolated to calcium channel interactions and an impairment 
of calcium-dependent membrane activity in the ileum (Bauman et al., 2000). Calcium-dependent 
channels allow the GIF bound Vitamin B12 to be taken up for further processing; the suggestion 
that metformin inhibits the action of these channels would create a barrier for the GIF bound B12 
and thus lead to malabsorption. However the study showed that while malabsorption decreased 
after calcium supplementation, there was no corresponding increase in serum Vitamin B12 level. 
The effect of calcium was not trialled independent of metformin and therefore may have an 
increasing effect on B12 absorption as opposed to a correcting of a metformin induced interaction. 
Even though the use of calcium would reverse the malabsorption it does not increase serum levels 
and is also potentially causes an increase in cardio vascular risk and therefore is not favoured, 
especially in patients with an already elevated risk level. 
In a contrasting perspective, Obeid.R et al. (2013) suggest that while patients with type 2 
diabetes may show a normal extracellular Vitamin B12 level, the intracellular markers used to 
measure the biochemical reactions in which Cbl takes place were abnormal compared with a 
control population (Obeid et al., 2013). It is further suggested that the use of metformin in type 2 
diabetes does not lead to malabsorption of the vitamin, but rather “cures” Vitamin B12 resistance 
which leads to the lowered intracellular concentrations of metabolites which indicates a lower 
biochemical usage of the vitamin. With this influx of Vitamin B12 into the cell the extracellular 
measurements (serum etc.) are seen to drop. This suggested that there is no lack or inhibition on 
the metabolic pathways that Cbl is required for.  The evidence provided for these claims was based 
on the red blood cell extracts and related metabolites of Cbl action (MMA, SAM/SAH ratio). It 
was observed that the metabolic markers for Vitamin B12 were lower in a population with diabetes 
(not on metformin) compared to a control population. The extra cellular markers were seen to be 
comparable or higher in the diabetic population. The population of patients with diabetes and taking 
metformin was seen to have a lower extracellular measurement (holotranscobalamin, serum 
Vitamin B12) but individuals seemed to have an improved cell content and metabolic profile of 
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Vitamin B12 (lower MMA, better methylation index) (Obeid et al., 2013). It is through this 
process of thought that the study suggests that Vitamin B12 congestion in blood is associated with 
intracellular deficiency, highlighted by elevated total homocysteine, leading to further evidence for 
the theory that there is cellular Vitamin B12 resistance in patients with type 2 diabetes. While there 
is currently no evidence for the claim that metformin uncovers the Vitamin B12 status in patients 
with type 2 diabetes, it is suggested that mechanisms such as changes to cellular membrane 
composition or alterations to the dynamics of glycosylation processes may hold the answer. The 
study concludes by claiming that metformin treatment is related not only to low serum Vitamin 
B12 but also to improvements in the intracellular Vitamin B12 content and markers for 
metabolism.  
An in vivo animal trial carried out by Greibe. E et al (2013) aimed to explore the potential 
for alternate absorption patterns for vitamin B12 caused by metformin exposure (Greibe, Miller, 
Foutouhi, Green, & Nexo, 2013). This study incorporated the use of a study population of 18 
Sprague Dawley rats. The rats were injected subcutaneously with either metformin or a saline 
control for 3 weeks. Following this exposure period the amount of Vitamin B12 was located and 
regionalized using radio-labelled B12. The results from the study reinforce what studies (Obeid et 
al., 2013) before have shown, that metformin treatment reduces serum Vitamin B12. It was found 
that a 22% reduction in Vitamin B12 levels was seen in rats exposed to metformin therapy for just 3 
weeks. However the mechanism of reduction of serum levels is not investigated thoroughly. This 
lowering of Vitamin B12 in the blood was thought to be attributed to an increase of Vitamin B12 in 
the livers of treated rats which showed a 36% increase in vitamin content compared to control rats. 
It is suggested that this result may be consistent in humans with diabetes and taking metformin, 
where the serum level of Vitamin B12 is decreased due to an increased absorption proficiency and 
displacement of Vitamin B12 to the liver. Furthermore the study shows that the total amount of 
absorbed Vitamin B12 in both rat populations (metformin vs. control) were comparable, further 
suggesting that there is no absence of absorption due to metformin but rather a redistribution of the 
vitamin. Kidneys in rats treated with metformin contained 36% less B12 than the control 
population, this was again attributed to increase in liver absorption.  While this study brings to light 
some very interesting ideas and hypotheses regarding the mechanism of metformin and Vitamin B12 
interaction, it has several very crucial limitations that need to be considered. While the use of 
animal subjects in such a trial is obviously a practical issue, the translation of such findings into 
human individuals may not mimic such observations as the pathogenesis of diabetes may be highly 
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variable between species. As suggested previously, if patients with type 2 diabetes have a cellular 
resistance to Vitamin B12 this study may fall short of addressing the reality of Vitamin B12 status in 
humans with diabetes. Most crucial to the application of this study was the mode of administration 
bypassing the gastric system. This is a key factor as it is thought that much of the metformin 
interaction occurs in the small bowel and/or the ileum (Bauman et al., 2000), thus the 
subcutaneous route may mask the potential malabsorption effect of metformin treatment.  
 
Vitamin B12 is suggested as a crucial factor in the maintenance of neuronal health and 
function and that deficiencies caused via avenues such as metformin treatment may corrupt the 
neuronal abilities of an individual. A study carried out by Chen et al (2012) explored the 
relationship between metformin use and altered neuronal function (Chen, 2012). A study group of 
202 patients with type 2 diabetes was split between those taking metformin for a period longer than 
6 months and a non-metformin group. Once again the metformin population yielded a lower serum 
Vitamin B12 level than that of the non-metformin group. Through several tests for neuropathy: 
history, vibration perception, s-LANSS (self-assessed Leeds Assessment of Neuropathic Symptoms 
and Signs) neuropathic pain etc. it was seen that there was no significant difference between the 
metformin and the non-metformin patients in regard to neuropathy. The author claims that diabetic 
peripheral neuropathy is clinically indistinguishable from Vitamin B12 related neuropathy, however 
the two study populations were all sourced from a general population who had all previously been 
diagnosed with diabetic neuropathy. This poses a boundary in the ability to perceive any differences 
in the neuropathic profiles of each of the populations as any increase or decrease in Vitamin B12 
neuropathy may be masked by the primary diagnosis of diabetic neuropathy. Furthermore it was 
seen that the metformin group had an overall lower ferritin level with significant difference to the 
control group (p=0.03). The study does make several suggestions in regards to the mechanism of 
Vitamin B12 reduction in metformin patients; alterations in bowel motility, bacterial overgrowth 
and possible inhibition of B12 absorption are all noted.  
While the above studies illustrate differing opinions on the mechanism of Vitamin B12 
alteration in metformin treated patients, there is much to be gained from this exploration into the 
kinetics of interaction. The potential for irreversible neuronal damage resulting from preventable 
loss of the vitamin as well as the increased risk of megaloblastic-anaemia (Callaghan & Hadden, 
1980) make it crucial that the prevalence for metformin induced Vitamin B12 malabsorption in 
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New Zealand be addressed. While Medsafe guidelines (Medsafe, 2009) and other studies (Mahajan 
& Gupta, 2010) suggest annual screening for B12 deficiency for all patients on metformin, this is 
thought to be rarely followed in practice. 
 
Clinically significant deficiency of Vitamin B12 is not flagged until the patient has a serum 
level of <148 pmol/L, however it has been observed that levels under 220 pmol/L should be 
considered as suboptimal and that may be indicative of levels that may lead to an inhibition of 
biological function (Mazokopakis & Starakis, 2012). For this reason a level of 220 pmol/L should be 
considered as eligible for treatment, this is further supported by evidence suggesting that serum 
level of Vitamin B12 do not accurately reflect a deficient amount of the vitamin(Obeid et al., 2013) 
thus false negatives for suboptimal Vitamin B12 may arise. Furthermore as with many health issues, 
an approach of preventative treatment should be adopted in which patients who are identified as 
borderline B12 (148 – 220 pmol/L) may develop a deficiency if the factors that have led to such a 
level are continued, i.e. metformin treatment. 
 
There is still much dispute about the clinical outcomes of the observed serum Vitamin B12 
decrease associated with long term metformin treatment. There is no available literature on the 
prevalence of such an association in a New Zealand population. Previous studies have rates of 
prevalence with vast differences depending on the study population and therefore the assessment of 
a New Zealand population will allow further understanding of factors that may be affecting the 
development of this deficiency. While studies completed have shown the differences between 
sublingual, oral and intramuscular treatment options for the treatment of Vitamin B12 deficiency 
(Yazaki et al., 2006; Delpre, Stark, & Niv, 1999; Sharabi, Cohen, Sulkes, & Garty, 2003; Yazaki, 
Chow, & Mattie, 2006), there is not a large amount of literature regarding the use of these 
treatments in the metformin associated Vitamin B12 deficiency. With the current mechanism of 
metformin interaction relying on malabsorption of the vitamin during digestion, the route of 
sublingual treatment may show results that differ from previous sublingual study which does not 
address such a mechanism and therefore exhibit results that may understate the role a sublingual 
treatment and the evasion of the digestive tract.   
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An evaluation of the levels of metformin associated Vitamin B12 deficiency in a New 
Zealand population will allow assessment on the prevalence as well as the factors affecting this 
decreased vitamin state. A direct comparison of sublingual based treatment against the traditional 
intra muscular route of administration will allow for investigation into the potential means of 
correcting a decreased serum Vitamin B12 level following long term metformin treatment in 
patients with type 2 diabetes mellitus. More in depth research also needs to be conducted into the 
outcomes of metformin related Vitamin B12 deficiency to assess whether the treatment of this is 
required in order to maintain regular Vitamin B12 functionality.   
 
This study will address the two main issues that have not been investigated in detail. A 
clinical audit and prevalence assessment will help identify the proportion of patients who are being 
treated with metformin over a long period of time who have developed a Vitamin B12 deficiency. 
This information will aid in knowledge of factors contributing towards increased risk factors of such 
a deficiency and aims to allow for a better understanding of how population demographics affect any 
differences in the rate of prevalence. Furthermore this study will draw direct comparisons of two 
different treatment options aiming to treat the acquired deficient state. This will allow not only the 
development of knowledge in this area but will also assess potential treatment options for the future 
treatment of patients afflicted by the interaction.  
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3.0 Methods 
This study addresses the previously observed and explored effect of long term metformin treatment 
on serum Vitamin B12 level for patients who have Type 2 Diabetes Mellitus. Through analysis of 
patients attending clinical appointments at Wellington Regional Hospital as well as assessment of 
patients in a primary care environment the investigation will add further information to our 
understanding of this association.  
 
The main objectives of the research are: 
- A: To identify the prevalence of lowered Vitamin B12 serum levels (<220 pmol/L) in 
patients who have Type 2 Diabetes in both a secondary care outpatient population and 
in a primary healthcare environment.  
- B: To evaluate the effectiveness of two treatment methods for patients identified with a 
lowered serum Vitamin B12 level in a randomised controlled trial. 
 
Ethics approval for the study was obtained from the Central Health and Disability Ethics Committee 
(reference: 12/CEN/65/AM02).   
The screening phase was undertaken as a clinical audit and therefore did not require individual 
patient consent.  All patients taking part in the randomised controlled trial gave written informed 
consent to take part. 
Funding for the project was obtained through a University of Otago research grant.  
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3.1 – Study 1 – Prevalence assessment 
 
To evaluate the prevalence of lowered Vitamin B12 levels (serum Vitamin B12 < 220pmol/L) in 
patient population in both secondary care and primary care environments and evaluate any 
relationships between factors of; duration of metformin treatment, dosage of metformin, patient 
demographics. 
 
3.1.1 – Screening 
All patients attending a Diabetes Clinic at Wellington Regional Hospital and Kenepuru Hospital 
between February 12th 2013 and February 12th 2014 were assessed for eligibility for investigation 
into prevalence of decreased serum Vitamin B12 level. Patients attending the clinic before August 
1st 2013 were also considered for Study 2 – Intervention Study, as detailed later. The flow of patients 
through the stages of screening and participation in the prevalence study is shown in Figure 3.1.1 
Patients investigated for prevalence were assessed on the following: 
Inclusion Criteria: 
- Diagnosis of Type 2 Diabetes 
- Treatment with metformin for a minimum duration of 12 months.  
Exclusion Criteria: 
- Diagnosis of Type 1 diabetes 
- Known existing megaloblastic anaemia 
- Existing Vitamin B12 treatment or supplementation 
 
Diagnosis of Type 2 Diabetes Mellitus was in accordance to the position statement released by the 
New Zealand Society for the Study of Diabetes (NZSSD) ("NZSSD Position Statement on the 
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diagnosis of, and screening for, Type 2 Diabetes," 2011) which has been adopted by the Ministry of 
Health New Zealand which is as follows: 
- In symptomatic individuals an HbA1c ≥50 mmol/mol (and, if measured, a fasting blood 
glucose of ≥ 7.0 mmol/l r a random glucose ≥ 11.1mmol/l) is sufficient to establish the diagnosis 
of diabetes 
- In asymptomatic individuals the same criteria apply but, to confirm the diagnosis of diabetes, a 
confirmatory test (preferably HbA1c) is needed on a separate occasion. 
 
If the patient met the inclusion criteria they were considered as Level 1 Eligible. All patients who 
were Level 1 Eligible were included in the prevalence study and a serum Vitamin B12 level 
sought from the laboratory records. All information obtained from screening is kept on a central 
database which relies on the unique NHI number for each patient. 
- If the obtained value for serum Vitamin B12 from within the previous 3 months was less 
than 220 pmol/L, the patient was approached with an offer to join the intervention 
study and deemed to be Level 2 Eligible 
- If the obtained value for serum Vitamin B12 from within the previous 3 months was 
220 pmol/L or higher the patient was included in the prevalence evaluation but deemed 
to be not eligible for the intervention study. 
- If there was no value for serum Vitamin B12 from within the previous 3 months then a 
blood test was requested by the doctor assessing the patient and the patient was added 
to a recall list labelled Recall Yellow to follow up the request.  
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3.1.2 – Primary Health Screening 
In order to increase recruitment and diversify the demographics included in the prevalence study, 
four primary health providers were approached by the research team. Through the practice 
management system (Medtech) an initial screen was conducted on the patient database of each 
practice. The software screening relied on the matching of Ministry of Health read codes used for 
diagnoses and medications with several input criteria. The input criteria used for this screening 
were as follows: 
- Diagnosis of type 2 Diabetes 
- Prescription of metformin Hydrochloride between 12/02/2012 and 12/02/2014 
This screen produced a list of patients who have been coded with a diagnosis of Type 2 Diabetes and 
who had received a prescription for metformin within the last year. These individuals were posted 
an invitation of study which included an explanation about the observed association between 
metformin and Vitamin B12. Patients who expressed interest were investigated in order to ensure 
that there was no current Vitamin B12 treatment and that they had been taking metformin for a 
minimum of 12 months. If a patient was eligible and still expressed interest in the study a blood test 
form was sent to the patient in order to evaluate their serum Vitamin B12.  
 
All patients who were deemed to be Level 1 Eligible were assessed for the following demographic 
data in order to assess factor affecting serum Vitamin B12 level: 
- Age 
- Gender 
- Ethnicity 
- Dosage of metformin (mg/day) 
- Duration of metformin treatment (years) 
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3.1.3 – Follow up – Level 1 Eligibility  
Level 1 Eligible patients who did not have a previous serum Vitamin B12 level within the last 3 
months and who were thus allocated to Recall Yellow were periodically reviewed to obtain a 
serum Vitamin B12 level. Patients who were on the Recall Yellow list for 1 month and still did 
not yield a serum Vitamin B12 level were sent a recall letter notifying them of the observed 
association of metformin use and serum Vitamin B12 deficiency. This letter included a blood test 
form for a Vitamin B12 test and these patients were then placed on the Recall Orange list. The 
Recall Orange list was periodically reviewed to obtain Vitamin B12 levels from patients, however 
no further contact with the patient was made. Any patient who produced a serum Vitamin B12 
level during the review period was allocated to either Level 2 Eligible (if serum Vitamin B12 
<220 pmol/L) or deemed non eligible (if serum Vitamin B12 ≥220 pmol/L). 
 
3.1.4 – Follow up – Level 2 Eligibility 
Patients who were identified as being Level 2 Eligible were invited to take part in the intervention 
study via their clinic physician, or via the researcher in the case of patients screened through 
primary health recruitment who had already expressed interest. If no answer was passed onto the 
research team in regards to the patients desire to take part, the patients were added to Recall Red 
list. This list worked much the same as the previous recall list in which a patient who had not 
notified their decision to participate were sent a follow up letter after one month. This letter 
advised of the association between metformin and serum Vitamin B12 deficiency and that the 
patient had been found to have a suboptimal Vitamin B12 level. The patient was invited to take part 
in the study via a response form. Once this invitation was sent, no further offer of invitation was 
made to the patient. 
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Figure 3.1.1 – Flow chart of patient screening and recruitment 
 
 
Diabetes Diagnosis 
Type 1 Diabetes - Not 
Eligible 
Type 2 Diabetes 
Other form of Diabetes - 
Not Eligible 
Metformin Treatment 
Treatment Duration less 
than 12 months - Not 
Eligible 
Treatment Duration more 
than 12 months 
LEVEL 1 ELIGIBLE 
Serum Vitamin B12 level 
Vitamin B12 serum level 
>219 - Not Eligible 
Vitamin B12 serum level 
<220 
LEVEL 2 ELIGIBLE 
No metformin Treatment - 
Not Eligible 
No serum Vitamin B12 
level in previous 3 months 
Recall Yellow 
Recall Orange 
Recall Red 
Clinic Visit 
LEVEL 3 ELIGIBLE 
RECRUITMENT 
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3.1.5 – Phlebotomy 
Patients who had been identified as Level 1 Eligible and who did not have a current serum 
Vitamin B12 level were approached by their physician for a test to be done.  The samples were 
analysed at either the CCDHB laboratory or if taken in the community by Aotea Pathology.  
The CCDHB laboratory uses the Roche Cobas e601 and competitive electrochemiluminescence 
(ECLIA) method for evaluation of serum Vitamin B12 level. The method is said to be accurate 
between the ranges of 22.0 – 1476 pmol/L (CV = ±5%) 
Aotea Pathology uses the Roche Modular E170 and the same competitive 
electrochemiluminescence immunoassay (CV = ±5%). 
 
As both of the test centres use the same method of assessment for serum Vitamin B12, and only 
differ in the type of analyser (also compatible) the results from both centres are claimed to be of 
equivalent accuracy. Full procedure is seen in Appendix A 
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3.2 – Study 2 - Intervention study 
 
A randomised control study of intramuscular injections of Hydroxocobalamin 1mg vs. sublingual 
treatment with Methylcobalamin 1mg/day, in patients with Type 2 Diabetes Mellitus who are 
being treated with metformin and have a current serum Vitamin B12 level of <220 pmol/L.  
Patients identified during Study 1 – Prevalence Study as having a decreased serum Vitamin B12 level 
who were seen before August 1st 2013 were invited to participate in an intervention study. The 
time frame allows for results of the 6 month trial to be available by study completion.  
3.2.1 – Clinic Visit 1 
Level 2 Eligible patients who accepted an invite to participate in the intervention study were 
booked an appointment with the research team in the Endocrine, Diabetes and Research Centre.  
After obtaining written informed consent further information was obtained. 
Inclusion criteria: 
- Type 2 Diabetes diagnosis 
- Treatment with metformin for 12 months or longer 
- Vitamin B12 of < 220 pmol/L 
Exclusion criteria: 
- Existing treatment for B12 deficiency 
- Folate deficiency or related anaemia 
- Pregnancy or lactation 
- Cobalamin allergy 
- Breach of Medsafe guidelines for safe administration of intramuscular injection of 
Hydroxocobalamin 
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Primary outcome measure was serum Vitamin B12 level at baseline, 3 month and 6 month time 
points. 
Secondary outcome measures were prevalence of decreased serum Vitamin B12 level, and 
Michigan Neuropathy Screening scores at baseline and 6 months. 
 
 If all the inclusion criteria and none of the exclusion criteria were met, and the patient was willing 
to participate in the study, the patient was deemed Level 3 Eligible and was included in the 
intervention study. Once patients were deemed eligible details are collected including key variable 
information, date of initial diagnosis, date of initial commencement of metformin, current 
metformin dosage, ethnicity, as well as additional medical information as seen in Appendix B. The 
patient was also required to sign a consent form. The Michigan screening tool is also used in order 
to evaluate the presence, if any, of neuropathy in the patient. The protocol for this screening tool is 
seen in Appendix C. This tool was used due to its ease of application and its acceptance as an 
adequate assessment of symptoms of neuropathy, verification and score boundaries are seen in Al-
Geffari et al (2012). 
Randomization was carried out using an internet based randomization tool (randomizer.org) to 
generate a random order sequence in the values of 1 or 2 to correspond to treatment groups. The 
sequence obtained was used in the order of patient recruitment. The investigators were not blinded 
to the randomization but the sequence was not altered during patient recruitment. 
Treatment 1 patients received a 1mg intramuscular injection of Hydroxocobalamin1 following 
CCDHB protocol. Treatment 2 patients were provided a 3 month course of sublingual 
Methylcobalamin supplements of a 1000 mcg/day dosage2. Patients also completed the University 
of Otago Food Questionnaire obtained from the Human Nutrition Department at Otago school of 
Medicine in order to assess if their background dietary intake at baseline. Appendix D.  
                                                             
1 Hydroxocobalamin ABM – Hydroxocobalamin acetate 
Solution for injection 1mg/mL – Ampoules of 1 mL containing 1 mg hydroxocobalamin acetate per mL equivalent 
to 0.96 mg of hydroxocobalamin per mL. Other ingredients: sodium chloride, sodium acetate, acetic acid, water for 
injections. 
http://www.medsafe.govt.nz/profs/datasheet/h/HydroxocobalaminABMinj.pdf 
 
2 Bronson Sublingual B12 1000mcg – Methylcobalamin 
Bronson Sublingual B12 provides this vitamin as Methylcobalamin. Extensive research studies show that 
Methylcobalamin is much more biologically active than cyanocobalamin 
http://www.healthpost.co.nz/supplements-and-natural-health/vitamins/vitamin-b/sublingual-b12-1000mcg--
methylcobalamin-nhb12 
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Due to the different treatment methods blinding of investigators and/or patients was not possible. 
However as the primary outcome variable was objective serum Vitamin B12 level it was not 
expected that blinding of patients or investigators would cause bias in this regard.   
If the patient desired, a letter was sent to their GP informing them of their involvement in the study 
as well as information about the research project.  Patients were provided with travel compensation 
as per the information sheet as seen in Appendix E. 
 
3.2.2 – Clinic Visit 2 
After 10 weeks from their first clinic visit patients were contacted to arrange a time for their second 
clinic visit. Patients were also sent a blood test form to assess their serum Vitamin B12 in order to 
evaluate the effect of the treatment to which they were assigned. The results from this blood test 
are intended to be available before the patients visit the clinic. At the second clinic visit the patients 
were told of their updated B12 level. If the B12 level of the patient had risen to above 220 pmol/L 
the patient was not provided additional treatment regardless of treatment group. If the patients 
latest B12 was still below 220 pmol/L they received a further treatment course of the same 
treatment to which they are allocated.  
 
If the patient desired, a letter was sent to their GP letting them know of the development of the 
study and the patient’s current Vitamin B12 level. 
 
3.2.3 – Clinic Visit 3 
At 23 weeks patients were contacted to arrange a time for their third clinic visit. Patients were once 
again sent a blood test form to assess their latest serum Vitamin B12 level. The Michigan screening 
tool was re-implemented to assess any potential change to the patients score as a result of the 
treatment. Patients were informed of their final B12 level and the pattern of change in their Vitamin 
B12 level was discussed with them. Any questions that the patient had concerning the study were 
addressed and the patient was discharged from the care of the researchers. 
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If the patient desired, the results were sent to their GP and the patient was discharged back into 
their GPs care.   
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Figure 3.2.1 – Patient flow chart for intervention for all comprehensively eligible patients 
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3.3 – Statistical Analysis 
 
All analysis of data was conducted through the use of IBM software SPSS 20.0. The primary 
outcome results are presented as means. Assessment for significance between means was tested 
through application of t –test. Univariate Analysis of Variance (ANOVA) was used to assess 
between group interactions. Correlation was assessed using Pearson (for normal distribution, linear 
correlation) and Spearman (for non-normal, non-linear correlation) tests as specified. Continuous 
variables were log transformed wherever possible before running tests that require normal 
distribution of the data. All tests were two-sided and p values of <0.05 were considered to be 
statistically significant. Post hoc assessment of multiple interactions was conducted by LSD as 
indicated. Logistic regression analysis was used for comparison of prevalence data due to the 
dichotomous property of the outcome variable.  Stepwise forward multiple regression analysis was 
applied to identify variables that predict serum Vitamin B12 level. Graphical representation of 
statistical significance was allocated in the following manner:  
* = p<0.05, ** = p<0.005, *** = p<0.0005.  
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4.0 Results – Prevalence of Vitamin B12 
Deficiency 
 
Study 1.  Prevalence of low Serum Vitamin B12 level in people with Type 2 DM on 
metformin therapy for at least 12 months. 
 
4.1 – Study population 
 
A total of 19,788 patients were screened from four Primary Health Providers in the Wellington 
region (Island Bay Medical Centre, Newtown Medical Centre, Karori Medical Centre Ltd., 
Newlands Medical Centre) and the Diabetes Outpatient Clinic at the Endocrine, Diabetes and 
Research Centre at Wellington Regional Hospital. 
 Screening through Primary Health Providers using Medtech 20 software identified 720 
Level 1 Eligible patients (confirmed diagnosis of Type 2 Diabetes Mellitus (DM) and treatment 
with metformin for a period of 12 months or more). Of these 720 patients, 108 were deemed 
ineligible by their general practitioners for reasons such as pregnancy, currently breastfeeding, 
significant mental health issues, complicating comorbidities (such as anaemia). The remainder were 
approached for investigation into prevalence of decreased Serum Vitamin B12 level. A total of 612 
invitations to study were sent out to the remaining eligible primary health care patients. Of the 
initial 612 initiations that were sent out, 117 patients indicated interest in the study and were 
contacted with further information and provided a blood test form. From which 98 patients 
completed the required blood test for Serum Vitamin B12.  
Screening through the Diabetes Centre at Wellington Regional Hospital resulted in the assessment 
of 1090 patients attending clinic. Of these 305 were deemed Level 1 Eligible and considered for 
serum Vitamin B12 level investigation. Of the initial secondary health population, 226 patients had 
a reported Vitamin B12 level in the previous 3 months or provided a current Serum Vitamin B12 
level during the study period.  
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Figure 4.1.1 – CONSORT Diagram of study to assess prevalence of lowered Serum Vitamin 
B12 level 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
19,788 Patients assessed for 
eligibility from primary and 
secondary health environment 
18,859 Patients excluded as 
deemed not eligible due to not 
meeting primary inclusion 
factors 
929 Patients deemed eligible for 
prevalence study 
420 Patients were offered 
evaluation of Serum Vitamin 
B12 level 
509 Patients excluded as they 
did not respond to invitation of 
the study  
96 Patients excluded as failed to 
provide Serum Vitamin B12 
level 
324 Patients provided Serum 
Vitamin B12 level 
260 Patients had normal Serum 
Vitamin B12 level (≥220 
pmol/L) 
64 Patients had suboptimal 
Serum Vitamin B12 level (<220 
pmol/L) 
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 The two study populations were similar in demographic composition but different in overall 
population size. Significant difference was seen in the variable of age (p = 0.008) where the patients 
recruited from the secondary healthcare environment were seen to be significantly younger than 
those from the primary healthcare environment (mean difference of 3.52 years). Both populations 
had a higher percentage of men than women. (Table 4.1.1) 
 
Table 4.1.1 – Demographics of patient populations included in prevalence study. Mean (SD) 
 
Primary Health 
n = 98 
Secondary Health 
n = 226 
Total Population 
n = 324 
Age (years) 63.93 (10.28) 60.41 (11.23)* 61.48 (11.06) 
Men - n (%) 57 (58%) 118 (52%) 175 (54%) 
Duration of 
metformin treatment 
(years) 
7.74 (4.33) 7.72 (4.15) 7.72 (4.20) 
Dosage of metformin 
(mg/day) 
1852.04 (696.27) 1998.67 (767.20) 1954.32 (748.43) 
Serum Vitamin B12 
(pmol/L) 
348.53 (177.56) 357.48 (185.08) 354.77 (182.62) 
* p<0.01 
 
In order to assess the factor of ethnicity in the prevalence of serum Vitamin B12 deficiency the New 
Zealand Ministry of Health ethnic identifiers were used. These are based on a numerical code for 
each ethnic group and are used nationally. Due to patient numbers the ethnic groups were 
combined for all ethnicities that had 10 or fewer individuals who identified with it. This resulted in 
6 different ethnic categories, here reported in order of coding: 11 – NZ European, 12 – Other 
European, 21 – NZ Maori, 31 – Samoan, 43 – Indian, All Others. The composition of different 
ethnicities present in each population was skewed greatly towards individuals who identified as NZ 
European; nearly half of each treatment group population was comprised of this ethnicity. There 
was no significant difference between treatment groups in regards to the proportions of different 
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ethnic groups; however there were differences between the numbers of patients in each ethnic 
group.  
 
Table 4.1.2 – Ethnicity composition of study population. Number of patients and percentage 
of group population 
Ethnicity 
Primary Health 
n = 98 
Secondary Health 
n = 226 
Total 
n = 324 
11 - NZ European 45 (45.9%) 99 (43.8%) 144 (44.4%) 
12 - Other European 10 (10.2%) 22 (9.7%) 32 (9.9%) 
21 - NZ Maori 13 (13.3%) 23 (10.2%) 36 (11.1%) 
31 - Samoan 6 (6.1%) 13 (5.8%) 19 (5.9%) 
43 - Indian 9 (9.2%) 28 (12.4%) 37 (11.4 %) 
Other 15 (15.3%) 41 (18.1%) 56 (17.3%) 
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Screening through the Diabetes Clinic at Wellington Regional Hospital also provided informative 
statistics on patient numbers visiting the secondary health service (Table 4.1.3). Of the unique 
individuals attending clinic during the study period 27.96% were seen to be eligible for 
investigation of serum Vitamin B12. 
 
Table 4.1.3 – Eligibility of patients attending Diabetes Clinic at Wellington Regional 
Hospital. Number of patients and percentages of screened population 
Criteria 
Number of Patients (% of secondary health 
screened population) 
Diabetes Diagnosis 1091 (100%) 
Type 2 Diabetes 533 (48.85%) 
metformin Use 368 (33.73%) 
Treatment Over 12 Months 305 (27.96%) 
Reported Vitamin B12 Level 226 (20.71%) 
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Figure 4.1.2 – Eligibility of patients attending Diabetes Clinic at Wellington Regional 
Hospital. Percentage of screened secondary health patients 
 
 
In total data for patients with type 2 DM receiving metformin therapy for more than 12 months 
were available for 324 patients (32.86 % of the total invited eligible population). This included 98 
from primary care (15.86% of eligible) and 226 from secondary care (74.10 % of eligible).   
 
Table 4.1.4 – Descriptive statistics for serum Vitamin B12 level across the study population 
Parameter Measurement (pmol/L) 
Minimum 80.00 
Maximum 1450.00 
Mean 354.77 
Std Deviation 182.62 
51.15% 
16.13% 
32.72% 
Type1/Other 
Type 2 - No Metformin 
Type 2 - Metformin Trearment >12 Months 
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Serum Vitamin B12 level were not seen to follow a normal distribution with a skewed pattern 
towards the left. Peak distribution is found to be within one standard deviation of the 220pmol/L 
value of decreased Vitamin B12 status. X –axis reference line has been added to show this level 
graphically: 
 
Figure 4.1.3 – Distribution of serum Vitamin B12 level for entire study population 
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Analysis of distribution of serum Vitamin B12 level suggest a log normal distribution 
 
Figure 4.1.4 – Q-Q plot for serum Vitamin B12 distribution showing log correction of data 
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Vitamin B12 levels for total study population were placed into 3 different categories based on 
clinical relevance of serum levels: Vitamin B12 Deficiency level (<150 pmol/L), Lowered Vitamin 
B12 level (150 – 219 pmol/L), and Normal Vitamin B12 level (≥220 pmol/L).  
 
Table 4.1.5 – Vitamin B12 levels in total study population n = 324. Number of patients and 
percentages of population 
Vitamin B12 Level Number of Patients 
Deficient (<150 pmol/L) 16 (4.9%) 
Lowered (150 -219 pmol/L) 48 (14.9%) 
Normal (≥220 pmol/L) 260 (80.2%) 
 
Figure 4.1.5 – Serum Vitamin B12 level in total population of eligible patients in accordance 
to above boundaries 
 
61.90% 11.43% 
3.81% 
22.86% 
Normal Lowered Deficient No Reported Level 
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A total of 64 patients from the total population of 324 patients showed decreased serum Vitamin 
B12 level, corresponding to a prevalence of 19.75% for a decreased serum Vitamin B12 level 
(<220 pmol/L). 
 
Figure 4.1.6 – Prevalence of decreased Vitamin B12 level in total population. Percentage of 
study population 
 
 
The values for serum Vitamin B12 were assessed on the variable of patient population source, 
whether the patient was assessed through a Primary Health Provider or whether they were a patient 
of the Diabetes Centre at Wellington Regional Hospital/Secondary Health Care. The patient 
population were found to be comparable between population portion of deficient and lowered 
serum Vitamin B12 status (p = 0.519, p = 0.619 respectively) 
 
80.25% 
19.75% 
Normal ≥220pmol/L Lowered <220pmol/L 
  
 
46 
 
Table 4.1.6 – Number and percentage of patients in each serum Vitamin B12 level group 
according to population group 
Vitamin B12 Level Number of Patients 
 
Primary Health 
n = 98 
Secondary Health Care 
n = 226 
Deficient (<150 pmol/L) 6 (6.1%) 10 (4.4%) 
Lowered (150-219 
pmol/L) 
15 (15.3%) 33 (14.6%) 
Normal (≥220 pmol/L) 77 (78.6%) 183 (81.0%) 
 
 
Figure 4.1.7 – Reported Vitamin B12 levels in patients investigated through Primary 
Health Care according to above boundaries 
  
78.4% 
15.5% 
6.2% 
Normal Lowered Deficient 
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Figure 4.1.8 – Reported Vitamin B12 levels in patients investigated through Secondary 
Health according to above boundaries 
 
 
 
Analysis of decreased serum Vitamin B12 level requires assessment of patients who have a serum 
level of below 220 pmol/L. The two patient populations were found to have a comparable level of 
prevalence for decreased serum Vitamin B12. Differences in prevalence between the two 
populations was seen to not be statistically significant (p = 0.626).  
 
 
81.0% 
14.6% 
4.4% 
Normal Lowered Deficient 
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Table 4.1.7 – Number of patients and percentage of populations with decreased Vitamin B12 
(<220 pmol/L) for each population group, showing percentage for prevalence of Vitamin 
B12 status 
 Patient Population 
 
Primary Healthcare 
n = 98 
Secondary Healthcare 
n = 226 
Number of patients (%) 21 (21.4%) 43(19.0%) 
 
 
 
Potential predictor variables were evaluated in order to investigate potential factors effecting serum 
Vitamin B12 level and the rate of prevalence of decreased levels of serum Vitamin B12. 
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4.2 – Effect of metformin Dosage on serum Vitamin B12 level 
and prevalence of lowered level 
 
Metformin is available in either 500mg or 850mg doses. The maximum daily dose is 3000mg. 
Therefore the data for dosage is not continuous but determined by multiples of the available tablet 
strengths. Data for dosage of metformin was taken as mg/day; this allows for assessment between 
populations regardless of specific treatment regimens.  
 
Figure 4.2.1 – Q-Q plot of metformin dosage data shows lack of variability between dosage 
levels 
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Figure 4.2.2 – Histogram of dosage of metformin data shows lack of normal distribution 
 
 
 
 
 
 
 
The mean dosage of metformin (mg/day) was slightly higher in the secondary health patient 
population, however this not seen to be significant (p = 0.224). Again there was no difference in 
serum Vitamin B12 level between populations (p = 0.560) 
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Table 4.2.1 – Mean dosage of metformin and mean serum Vitamin B12 level for different 
populations 
 Mean (SD) 
 
Primary Health 
n = 98 
Secondary Health 
n = 226 
Dosage (mg/day) 1852.04 (696.27) 1998.67 (767.20) 
Serum Vitamin B12 (pmol/L) 348.53 (177.57) 357.48 (185.08) 
 
Correlation between categorized dosage of metformin and serum Vitamin B12 level was seen with 
Pearson’s co-efficient of -0.178 (p = 0.001), however due to the abnormal distribution of the 
metformin dosage data this should be interpreted with caution. 
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Figure 4.2.3 –Observed linear regression of metformin dosage and serum Vitamin B12 level 
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Metformin doses are dependent on pharmaceutical availability of drug; therefore distribution of 
values is not natural. An assessment of different ranges of drug dosage was carried out to further 
test the variable. 
 
Metformin dosages were assigned to six different categories dependant on the gram/day value. The 
general decrease in serum Vitamin B12 level as metformin dose increased was reflected in ANOVA 
assessment (p = 0.036) (Table 4.2.1). Post hoc (LSD) analysis of the difference between separate 
categories (Table 4.2.2) showed significant differences between the serum Vitamin B12 level of 
patients in the following interactions: 
- <1000mg/day vs. ≥3000mg/day (p = 0.011) 
- 1000-1499mg/day vs. ≥3000mg/day (p = 0.008) 
- 1500-1999mg/day vs. ≥3000mg/day (p = 0.046) 
 
 
Table 4.2.2 – Categorization of metformin dosage with mean serum Vitamin B12 
 
metformin Dosage 
(mg/day) 
Serum Vitamin B12 
(pmol/L)(SD) 
<1000 
n = 14 
445.93 (226.86) 
1000-1499 
n = 64 
389.98 (192.21) 
1500-1999 
n = 36 
379.50 (192.95) 
2000-2499 
n = 119 
341.26 (156.96) 
2500-2999 
n = 24 
334.79 (168.25) 
≥3000 
n = 67 
319.97 (197.84) 
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Figure 4.2.4 - Categorization of metformin dosage with mean serum Vitamin B12 level 
 
 
 
 
* = p<0.05, ** = p<0.005, *** = p<0.0005.  
 
 
 
 
 
 
 
* 
* 
* 
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As there was an observed interaction between the grouped metformin dosages and serum Vitamin 
B12 an analysis of the effect of grouped metformin dosage on the rate of prevalence of lowered 
serum Vitamin B12 serum was conducted. 
 
Logistic regression shows significant effect of metformin dosage on prevalence of decreased serum 
Vitamin B12 level (<220 pmol/L) (p = 0.031).  
 
Categorization was again implemented to further analyse interactions at between different levels of 
dosage (Table 4.2.3). Categorized dosage of metformin treatment was shown to be significant 
through logistic regression (p = 0.033). Chi square analysis showed no specific group comparison 
showed significant difference in prevalence of decreased Vitamin B12 status (<220 pmol/L). 
 
 
 
Table 4.2.3 - Categorization of metformin dosage with rate of prevalence of decreased serum 
Vitamin B12 level (<220 pmol/L) 
 
metformin Dosage 
(mg/day) 
Prevalence of 
lowered level 
<1000 
n = 14 
7% 
1000-1499 
n = 64 
14% 
1500-1999 
n = 36 
19% 
2000-2499 
n = 119 
19% 
2500-2999 
n = 24 
25% 
≥3000 
n = 67 
27% 
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Figure 4.2.5 - Categorization of metformin dosage with rate of prevalence of decreased 
serum Vitamin B12 level (<220 pmol/L) 
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Odds ratio calculation shows increase in chance of lowered serum Vitamin B12 level (<220 
pmol/L) with increase in dosage of metformin for most steps of 500mg/day 
 
Table 4.2.4 – Odds ratio for decreased serum Vitamin B12 status (<220pmol/L) for each 
500 mg increase in dosage of metformin 
metformin Dosage 
(mg/day) 
Comparative 
metformin Dosage 
(mg/day) 
Odds Ratio of 
decreased Vitamin 
B12 status 
(cases assessed) 
<1000 
n = 15 
1000-1499 
n = 63 
2.04 (78) 
1000-1499 
n = 63 
1500-1999 
n = 35 
1.75 (98) 
1500-1999 
n = 35 
2000-2499 
n = 114 
0.96 (149) 
2000-2499 
n = 114 
2500-2999 
n = 24 
1.39 (138) 
2500-2999 
n = 24 
≥3000 
n = 66 
1.12 (90) 
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4.3 – Effect of duration of metformin treatment on serum 
Vitamin B12 level and prevalence of lowered level 
 
The distribution of data for the duration of metformin treatment was seen to be very irregular. The 
data did not match normal or log normal distribution expectations or assumptions.  
 
Figure 4.3.1 – Q-Q plot of duration of metformin treatment showing non-normal 
distribution 
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Figure 4.3.2 – Log normal distribution of duration of metformin treatment showing 
insufficient log transformation of data to normality  
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Figure 4.3.3 – Distribution of duration of metformin treatment 
 
 
 
 
 
 
 
 
 
Analysis of correlation between duration of metformin treatment and serum Vitamin B12 level 
resulted in significant linear regression between the two variables by Pearson Correlation. Pearson 
Correlation Coefficient = -0.112 (p = 0.044) 
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Figure 4.3.4 – Scatter of data for duration of metformin treatment and serum Vitamin B12 
level showing linear correlation 
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Categorization of duration of metformin treatment was carried out to allow for irregular 
distribution of data. Data were assigned to one of five different time periods for duration of 
metformin treatment: 1.0-2.9 years, 3.0-4.9 years, 5.0-6.9 years, 7.0-8.9 years and ≥9.0 years.  
 
Difference between groups was seen to be significant (ANOVA p = 0.075). Post hoc (LSD) analysis 
identified significant difference between the following duration groups: 
- 3.0-4.9 years vs. ≥9.0 years (p = 0.048) 
- 5.0-6.9 years vs. ≥9.0 years (p = 0.038) 
 
 
Table 4.3.1 – Mean serum Vitamin B12 level (pmol/L) by categorized duration of metformin 
use 
 
Duration of metformin 
treatment (years) 
Serum Vitamin B12 
(pmol/L)(SD) 
1.0 – 2.9 
n = 49 
361.59 (135.37) 
3.0 – 4.9 
n = 51 
391.18 (192.22) 
5.0 – 6.9 
n = 52 
402.96 (258.43) 
7.0 – 8.9 
n = 52 
328.54 (174.88) 
≥9.0 
n = 120 
327.01 (152.28) 
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Figure 4.3.5 – Mean serum Vitamin B12 level (pmol/L) with 95% confidence interval by 
categorised duration of metformin serum use 
 
 
 
* = p<0.05, ** = p<0.005, *** = p<0.0005.  
 
 
 
 
As there was an observed interaction between categorical duration of metformin treatment and 
serum Vitamin B12 level, an analysis of prevalence was undertaken to investigate a translation of 
altered serum Vitamin B12 level to decreased Vitamin B12 status.  
Through logistic regression no significant difference was seen between the rate of prevalence of 
lowered serum Vitamin B12 level and categorical duration of metformin treatment (p = 0.081).  
Chi square analysis showed no specific group comparison showed significant difference in 
prevalence of decreased Vitamin B12 status (<220 pmol/L).
* 
* 
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Table 4.3.2 - Categorization of duration of metformin for prevalence of lowered serum 
Vitamin B12 level (<220 pmol/L) 
Duration of metformin 
treatment (years) 
Prevalence of 
lowered level 
2.0 – 2.9 
n = 48 
14% 
3.0 – 4.9 
n = 50 
20% 
5.0 – 6.9 
n = 52 
13% 
7.0 – 8.9 
n = 51 
19% 
≥9.0  
n = 116 
25% 
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Figure 4.3.6 - Categorization of metformin dosage with rate of prevalence of decreased 
serum Vitamin B12 level (<220 pmol/L) 
 
 
Assessment of odds ratio across different categories of duration of metformin treatment shows 
trend towards incremental increase in odds of prevalence towards the longer period of metformin 
treatment. 
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Table 4.3.3 – Odds ratio for decreased Vitamin B12 status (<220 pmol/L) by categorized 
duration of metformin use relative to  
 
Duration of metformin 
treatment (years) 
Comparative 
Duration of 
metformin treatment 
(years) 
Odds Ratio of 
decreased Vitamin 
B12 status 
(cases assessed) 
1.0 – 2.9 
n = 48 
3.0 – 4.9 
n = 50 
1.75 (98) 
3.0 – 4.9 
n = 50 
5.0 – 6.9 
n = 52 
0.66 (102) 
5.0 – 6.9 
n = 52 
7.0 – 8.9 
n =51 
1.57 (103) 
7.0 – 8.9 
n =51 
≥9.0 
n = 116 
1.37 (167) 
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4.4 – Effect of ethnicity on serum Vitamin B12 level and 
prevalence of lowered level 
 
There were various interactions between the variable of ethnicity and that of serum Vitamin B12 
level. Ethnicity as an independent variable was seen to significantly correlate with the variables of 
serum Vitamin B12 level and age (ANOVA p < 0.0005 and p = 0.001 respectively). 
 
Table 4.4.1 – Ethnicity dependent presentation of mean values of data for entire study 
population 
Ethnicity 
Mean level (SD) 
Serum 
Vitamin B12 
(pmol/L) 
metformin 
Dosage 
(mg/day) 
Duration of 
metformin 
Treatment (years) 
Age 
(years) 
NZ European 
n = 144 
315.89 
(131.68) 
1911.81 
(751.18) 
7.71 
(4.34) 
62.71 
(9.76) 
Other European 
n = 32 
333.09 
(166.53) 
1714.06 
(642.48) 
6.82 
(3.89) 
67.46 
(12.25) 
NZ Maori 
n = 36 
429.67 
(196.77) 
2181.94 
(782.41) 
7.69 
(4.38) 
59.14 
(10.20) 
Samoan 
n = 19 
499.90 
(203.39) 
2007.89 
(568.69) 
8.22 
(3.64) 
60.40 
(8.19) 
Indian 
n = 37 
364.03 
(284.24) 
1987.74 
(739.41) 
7.83 
(4.13) 
56.63 
(11.73) 
Other 
n = 56 
363.64 
(169.59) 
2014.64 
(811.77) 
8.05 
(4.09) 
59.96 
(12.70) 
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There were numerous significant differences in mean serum Vitamin B12 level when considering 
ethnicity as a predictor variable. These are expressed in (Figure 4.4.1) 
 
Figure 4.4.1 – Differences in mean serum Vitamin B12 level for different ethnic categories 
(CI = 95%) 
 
 
 
 
* = p<0.05, ** = p<0.005, *** = p<0.0005.  
 
 
 
*** 
** 
** 
*
* 
* 
***
* 
** 
  
 
69 
 
There were numerous significant differences in mean age when considering ethnicity as a predictor 
variable. These are expressed in (Figure 4.4.2). As can be seen, a majority of these are due to the 
significantly older Other European population.  
 
 
Figure 4.4.2 – Differences in mean age for different ethnic categories (CI = 95%) 
 
 
 
* = p<0.05, ** = p<0.005, *** = p<0.0005.  
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As there was significant interaction between the variables of ethnicity and serum Vitamin B12 level, 
further analysis was undertaken to evaluate whether this influence translated into a difference in 
prevalence of decreased serum Vitamin B12 level (<220 pmol/L) across the population (Table 
4.4.2) 
 
Linear regression shows that the prevalence of low serum B12 (<220 pmol/L) shows no significant 
differences across all ethnic populations (p = 0.963). 
Chi square analysis showed no specific group comparison showed significant difference in 
prevalence of decreased Vitamin B12 status (<220 pmol/L), the largest mean difference, between 
Samoan and Indian groups, having a p value of 0.07. 
 
Table 4.4.2 – Prevalence of lowered serum Vitamin B12 (<220 pmol/L) dependent on 
patient ethnicity for the entire study population 
 
Ethnicity 
Prevalence (%) of low serum Vitamin B12 
level (<220 pmol/L) within ethnic groups 
Group population 
NZ European 22% 144 
Other European 19% 32 
NZ Maori 11% 36 
Samoan 5% 19 
Indian 27% 37 
Other 21% 56 
Total 20% 324 
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Figure 4.4.3 - Prevalence of lowered serum Vitamin B12 (<220 pmol/L) dependent on 
patient ethnicity for the entire study population 
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4.5 – Effect of age on serum Vitamin B12 level and prevalence 
of lowered level 
 
Linear regression did not identify age as a predictor of serum Vitamin B12 level (p = 0.064). 
However a correlation assessment using Spearman test resulted in a co-efficient value of -0.121 (p 
= 0.030) suggesting that there may be a non-linear correlation between the two variables with a 
decrease in serum Vitamin B12 with an increase in age.   
Logistic regression identified increase in age as a predictor of lowered serum Vitamin B12 status 
(<220 pmol/L) (p = 0.047). 
 
Figure 4.5.1– Scatter plot of data on age vs. serum Vitamin B12 level (pmol/L) 
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Categorization of age of patient was conducted to assist in analysis. Patients were allocated into the 
following age groups: 30-50 years, 50-70 years, 70-90 years. There was no overall significant 
prediction of serum Vitamin B12 by categorized age (p = 0.120). Post hoc (LSD) analysis showed 
significant difference between serum Vitamin B12 level between patients of 30-50 years of age and 
70-90 years of age (p = 0.040).  
 
Table 4.5.1 – Mean serum Vitamin B12 (pmol/L) dependent on age group categorization 
 
Age range (years) 
Mean serum Vitamin B12 level (<220 
pmol/L) (SD) 
Group population 
(% of study 
population) 
30-50 382.96 (158.97) 49 (15.12%) 
50-70 357.18 (195.19) 199 (61.42%) 
70-90 330.32 (160.39) 76 (23.46%) 
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Figure 4.5.2 – Mean serum Vitamin B12 level (pmol/L) according to categorized age groups 
 
 
 
* = p<0.05, ** = p<0.005, *** = p<0.0005.  
 
 
 
 
* 
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Logistic regression suggests that there is an influence of categorized age and prevalence of decreased 
serum Vitamin B12 level (<220 pmol/L) (p = 0.038). Chi square assessment showed significant 
difference between the age groups of 30-50 years vs. 70-90 years (p = 0.019) 
 
Table 4.5.2 – Prevalence of lowered serum Vitamin B12 (<220 pmol/L) dependent on age 
group categorization 
 
Age range (years) 
Prevalence (%) of low serum Vitamin B12 
level (<220 pmol/L) within age group 
Group population 
(% of study 
population) 
30-50 8% 49 (15.12%) 
50-70 21% 199 (61.42%) 
70-90 25% 76 (23.46%) 
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Figure 4.4.3 - Prevalence of lowered serum Vitamin B12 (<220 pmol/L) dependent on 
categorised age of patient 
 
 
* = p<0.05, ** = p<0.005, *** = p<0.0005.  
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Table 4.5.3 – Odds ratio for decreased Vitamin B12 status (<220 pmol/L) by categorized 
age of patient  
 
Age of patient (years) 
Comparative age of patient 
(years) 
Odds Ratio of decreased 
Vitamin B12 status 
(cases assessed) 
30-50 
n = 49 
50-70 
n = 199 
2.19 (245) 
50-70 
n = 199 
70-90 
n = 76 
1.285 (275) 
 
Patients who were 65 years or older were seen to have a lower mean serum Vitamin B12 level and 
higher rate of prevalence for a lower serum Vitamin B12 level (Table 4.5.1). These differences 
however were not statistically significant (Linear regression p = 0.138 and Chi square p = 0.114 
respectively). 
  
Table 4.5.4 – Proportion of elderly patients and the apparent effect on mean serum Vitamin 
B12 level and prevalence of decreased level 
 
Age Parameter 
Mean serum Vitamin B12 
level (pmol/L)(SD) 
Prevalence of lowered 
level (<220 pmol/L)(% of 
population) 
<65 years  
n = 201 
363.26 (182.15) 17% 
≥65 years 
n = 123 
340.90 (183.31) 24% 
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Age was seen to be correlated with dosage of metformin (mg/day) with Pearson correlation 
coefficient of -15.75 (p < 0.0005) in linear regression. Age was also seen to be correlated with 
duration of metformin treatment (years) with Pearson correlation coefficient of 0.259 (p < 
0.0005). 
This interaction between age of patient, dosage of metformin and duration of metformin treatment 
may interfere with results from serum Vitamin B12 level investigation as dosage of metformin and 
duration of metformin use are seen to impact serum Vitamin B12 level. The association between 
these three variables is illustrated below (Figure 4.5.3). 
 
 
  
 
79 
 
Figure 4.5.3 – Association between patient age and dosage of metformin and corresponding 
mean serum Vitamin B12 level (pmol/L) 
 
 
 
 
 
 
 
 
Adjustment for age in linear regression of dosage of metformin and serum Vitamin B12 indicated 
that the correlation remains significant (p < 0.0005) 
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Figure 4.5.4 – Association between patient age and duration of metformin treatment and 
corresponding mean serum Vitamin B12 level (pmol/L) 
 
 
 
 
 
 
 
Adjustment for age in linear regression of duration of metformin and serum Vitamin B12 indicated 
that the correlation is insignificant (p = 0.051) 
 
 
 
 
  
 
81 
 
5.0 Results – Randomized Control Trial 
 
Study 2.  Treatment of decreased serum Vitamin B12 (<220 pmol/L) using a 
randomized control trial 
 
5.1 – Population Overview 
 
Of the 19 patients enrolled in the randomized control trial, a total of 17 patients completed the 
study by the end of the study period. Of these patients; 7 had been randomized to the 1 mg 
Hydroxocobalamin intramuscular injection group (Treatment 1) and 10 had been randomized to 
the Bronsons Sublingual Methylcobalamin B12 Supplement 1000mcg/day group (Treatment 2). 
 
Figure 5.1.1 – CONSORT diagram of intervention study 
 
 
 
 
 
 
 
 
 
 
19 Patients Recruited 
1 Patient lost to follow up 
1 Patient withdrawn due to 
unrelated health reason 
7 Patients 
Treatment Group 1 
Hydroxocobalamin injection 
(1mg) 
10 Patients 
Treatment Group 2 
Methylcobalamin daily 
sublingual supplements 
(1000mcg/day) 
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The demographic composition of the two treatment groups was comparable with no significant 
differences in any of the key variables. The most significant difference between the groups was in 
the variable of dosage of metformin where patients in Hydroxocobalamin injection treatment group 
had a higher mean dosage than those in Methylcobalamin sublingual treatment group = (0.224). As 
the two populations have comparable compositions any differences in outcome variables can is 
likely to be attributed to the treatment provided. 
These was a disproportionate number of male patients in both treatment groups, however there 
was no difference between the genders in regards to clinical measurements.  
 
Table 5.1.1 – Demographics of treatment group populations  
Variable 
Treatment Group 
Total 
Hydroxocobalamin 
Injection 
n = 7 
Methylcobalamin 
Sublingual 
n = 10 
Age (years) 65.60 (8.61) 61.50 (8.22) 63.19 (8.37) 
Gender – n (male) (%) 6 (85.71%) 6 (60%) 12 (70.59%) 
Healthcare source – n 
(primary) (%) 
4 (57.14%) 6 (60%) 10 (58.82%) 
Dosage of metformin 
(mg/day) (SD) 
2328.57 (949.94) 1905 (403.08) 2079.41 (689.90) 
Duration of metformin 
treatment (years) (SD) 
12.36 (5.49) 10.64 (5.50) 11.35 (5.39) 
Baseline serum Vitamin 
B12 (pmol/L) (SD) 
157.43 (42.20) 176.70 (36.51) 168.76 (38.90) 
Insulin treatment – n 
(treated) (%) 
3 (42.86%) 4 (40%) 7 (41.18%) 
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Within the study population the baseline serum Vitamin B12 level ranged from a minimum of 80 
pmol/L to a maximum of 219 pmol/L, mean value 168.76 pmol/L (SD = 38.90). Patients were 
randomized to treatment groups without baseline serum Vitamin B12 level stratification.  
Mean Serum Vitamin B12 level at baseline for patients was seen to not be significantly different 
between treatment groups (p=0.333).  
Of the 3 patients who were classed as clinically deficient (Serum Vitamin B12 <140 pmol/L); 2 
were in Hydroxocobalamin injection treatment group and 1 was in Methylcobalamin sublingual 
treatment group. 
 
Figure 5.1.2 – Illustration of serum Vitamin B12 status of entire patient population patients 
and commencement of study according to parameters outlined by Mezakopakis et al 2013 
 
 
 
 
24% 
76% 
Deficient (<150pmol/L) Lowered (150-220 pmol/L) 
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Study protocol required retreatment of patients if serum Vitamin B12 level at 3 months was less 
than 220 pmol/L. Two patients were hence retreated at 3 months and therefore the results for 
serum Vitamin B12 at 6 months were omitted from the statistical analysis due to increased 
treatment compared to the rest of the study population.  
Serum Vitamin B12 level for the patients recruited in the randomized control trial were recorded at 
Month 3, and Month 6.  
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5.2 – Raw data of Randomized Control Trial 
 
Serum levels changed in Hydroxocobalamin injection treatment group and Methylcobalamin 
sublingual treatment group significantly (p = 0.003, p < 0.005 respectively) at the 3 month time 
period compared to baseline levels. 
Serum Vitamin B12 level at 3 months were seen to be significantly different between the two 
treatment groups (ANOVA p = 0.014). 
Serum levels changed in Hydroxocobalamin injection treatment group and Methylcobalamin 
sublingual treatment group significantly (p = 0.006, p < 0.0005 respectively) at the 6 month time 
period compared to baseline levels. 
Serum Vitamin B12 at 6 months were insignificantly different between treatment groups (p = 
0.588) 
 
 
Table 5.2.1 – Mean serum Vitamin B12 level (pmol/L) for treatment groups at baseline and 
different time points 
Treatment Group  Serum Vitamin B12 (pmol/L) 
  Baseline 3 Month 6 Month 
Hydroxocobalamin 
Injection 
Mean 157.43 282.14 248.20 
Std Deviation 42.20 135.25 26.44 
N 7 7 5 
Methylcobalamin 
Sublingual 
Mean 176.70 406.60 268.60 
Std Deviation 36.51 80.77 59.97 
N 10 10 10 
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Figure 5.2.1 – Graphical representation of raw serum Vitamin B12 level (pmol/L) at each 
time point during the study period. Red line represents the 220 pmol/L level which is 
considered to be the lower limit of normal serum Vitamin B12 level.  
 
 
 
 
 
 
* = p<0.05, ** = p<0.005, *** = p<0.0005.  
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Figure 5.2.2 – Graphical representation of mean Serum Vitamin B12 level (pmol/L), 
illustration of peak differences between treatment groups over the duration of the study 
period (CI not shown) 
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5.3 – Baseline Correction of serum Vitamin B12 level 
 
As the mean baseline Serum Vitamin B12 level of patients were not stratified between treatment 
groups further analysis of the B12 levels was made assuming a 0 pmol/L level baseline and 
exploring the change in serum Vitamin B12 level between treatment groups. 
Both of the treatment groups showed increased mean values for Serum Vitamin B12 level at the 3 
month time point. Hydroxocobalamin injection treatment group exhibited a mean increase of 
124.71 pmol/L (SD 118.77). Methylcobalamin sublingual treatment group exhibited a mean 
increase of 229.90 pmol/L (SD 96.93)  
 
Hydroxocobalamin injection treatment group had an insignificant mean decrease from the 3 month 
time point to 70.20 pmol/L (SD 30.37) above baseline at the 6 month time point (p = 0.084). 
Methylcobalamin sublingual treatment group had a significant mean decrease from the 3 month 
time point to 91.90 pmol/L (SD 54.85) above baseline at the 6 month time period (p = 0.002). 
 
Change in serum Vitamin B12 level at 3 months were seen to be significantly different between the 
two treatment groups (p = 0.009) after correction for baseline. 
Change in serum Vitamin B12 level at 6 months were seen to be not significantly different between 
the two treatment groups (p = 0.057) after correction for baseline. 
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Table 5.3.1 – Mean change in serum Vitamin B12 level (pmol/L) from baseline at 3 month 
and 6 month time points 
    
Treatment Group  
Serum Vitamin B12 level (pmol/L) 
3 month time point 6 month time point 
Hydroxocobalamin 
Injection 
Mean 124.71 70.20 
Std. Deviation 118.77 30.37 
N 7 5 
Methylcobalamin 
Sublingual 
Mean 229.90 91.90 
Std. Deviation 96.93 54.85 
N 10 10 
 
Figure 5.3.1 – Graphical representation of change in serum Vitamin B12 level (pmol/L) 
between treatment groups after baseline correction 
 
** 
* 
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* = p<0.05, ** = p<0.005, *** = p<0.0005.  
 
Figure 5.3.2 – Graphical representation of changes in Serum Vitamin B12 level (pmol/L) 
between treatment groups over study period after baseline correction (CI not shown) 
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Due to the single outlying patient SCK015 who was randomized to Hydroxocobalamin injection 
treatment group the data analysis has potentially been skewed. Statistical analysis has suggested the 
case to be an abnormal result. 
Analysis of this case found a Cooks distance of 0.839 suggesting that the case may be an outlier and 
can therefore be omitted with caution.  
 
Figure 5.3.3 – Box plot of serum Vitamin B12 level (pmol/L) at 3 month time point for both 
treatment options showing presence and confirmation of SCK015 outlier 
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Revised results for mean change in serum Vitamin B12 from baseline at 3 months indicated 
significant difference between treatment groups (p < 0.0005) 
Difference in mean change of serum Vitamin B12 from baseline was significant between the 
treatment groups at the 6 month time point (p = 0.042) 
Difference in corrected serum Vitamin B12 level for Hydroxocobalamin injection treatment group 
from the 3 month time point to the 6 month time point was still insignificant (p = 0.139) 
 
Table 5.3.2 – Corrected mean change in serum Vitamin B12 level (pmol/L) from baseline at 
3 month and 6 month time points 
Treatment  3 months (pmol/L) 6 months (pmol/L) 
Hydroxocobalamin 
Injection 
Mean 80.83 65.50 
Std. Deviation 27.43 32.91 
N 6 4 
Methylcobalamin 
Sublingual 
Mean 229.90 91.90 
Std. Deviation 96.93 54.85 
N 10 10 
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Figure 5.3.4 – Corrected chart of change in Vitamin B12 levels (pmol/L) from baseline for 
treatment groups when single identified potential outlier is excluded from analysis.  
 
 
 
 
* = p<0.05, ** = p<0.005, *** = p<0.0005.  
 
 
 
 
 
*** 
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5.4 – Analysis of ΔB12 over 3 month time period 
 
In order to further assess the effect of the two treatment options on serum Vitamin B12 level, an 
analysis of short term changes in serum Vitamin B12 level was conducted. This was done by 
evaluating the difference in serum Vitamin B12 level from the result 3 months previous: 
3 month ΔB12 = serum Vitamin B12 at 3 months – baseline serum Vitamin B12 level 
6 Month ΔB12 = serum Vitamin B12 at 6 months – serum Vitamin B12 at 3 months 
 
There was no significant difference between the 3 month ΔB12 and 6 month ΔB12 for 
Hydroxocobalamin injection treatment group (p = 0.118) 
There was significant difference between the 3 month ΔB12 and 6 month ΔB12 for 
Methylcobalamin sublingual treatment group (p < 0.0005) 
The difference in 3 Month ΔB12 between the treatment groups was seen to be not significant (p = 
0.063) 
The difference in 6 Month ΔB12 between the treatment groups was seen to be not significant (p = 
0.345) 
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Table 5.4.1 – ΔB12 (pmol/L) for each time point between the different treatment groups 
    
Treatment  
ΔB12 at 3 months 
(pmol/L) 
ΔB12 at 6 months 
(pmol/L) 
Hydroxocobalamin 
Injection 
Mean 124.71 -79.6 
Std. Deviation 118.77 124.56 
N 7 5 
Methylcobalamin 
Sublingual 
Mean 229.90 -138.00 
Std. Deviation 96.93 100.94 
N 10 10 
 
Figure 5.4.1 – Representation of ΔB12 (pmol/L) levels for the study period for each 
treatment group.  
 
*** 
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* = p<0.05, ** = p<0.005, *** = p<0.0005.  
 
Once again the results for the patient SCK015 were excluded to evaluate any potentially masked 
correlation between treatment and ΔB12.  
 
Revised values for ΔB12 at 3 month time point were significantly different between the treatment 
groups (p value = 0.003),  
Differences between treatment groups were not significant for ΔB12 at 6 month time point (p value 
= 0.051) 
Corrected difference in ΔB12 for Hydroxocobalamin between 3 and 6 month time points was seen 
to be significant (p = 0.014) 
 
Table 5.4.2 Revised values for ΔB12 (pmol/L) at time points for each treatment group 
    
Treatment  
ΔB12 at 3 months 
(pmol/L) 
ΔB12 at 6 months 
(pmol/L) 
Hydroxocobalamin 
Injection 
Mean 80.83 -24.75 
Std. Deviation 27.43 25.11 
N 6 4 
Methylcobalamin 
Sublingual 
Mean 229.90 -138.00 
Std. Deviation 96.93 100.95 
N 10 10 
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Figure 5.4.2 – Modified graph of ΔB12 (pmol/L) during study period after exclusion of 
potential outlier from assessment 
 
 
* = p<0.05, ** = p<0.005, *** = p<0.0005.  
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5.5 – Treatment of Vitamin B12 deficiency 
 
Evaluation of the effect of each of the treatment options in alleviation of decreased serum Vitamin 
B12 level (<220pmol/L) was carried out. Patients were assessed on whether their level for Serum 
Vitamin B12 at 3 and 6 months was above 220 pmol/L or not. If the level was above this level the 
patient Vitamin B12 was deemed “resolved”. In some instances patients who were “resolved” at 3 
months had levels that were below 220 pmol/L at 6 months, these patients were therefore no 
longer considered “resolved” at the 6 month time point. The patients who were not “resolved” at 3 
months received an additional treatment; these results were omitted from the population at the 6 
month time period. This method allows for the analysis of long term resolution.  
 
Hydroxocobalamin injection treatment group had success rate of 71.4% patient resolution rate at 3 
months. Of those patients who were resolved at 3 months, resolution at 6 months was 80.0%. 
 
Methylcobalamin sublingual treatment group had a 100% patient resolution rate at 3 months. 
Resolution at 6 months was 75% of the group population.  
 
Difference between resolution rates of treatment groups was assessed using Chi square tests. 
Resolution rate at 3 months was not significantly different between groups (p = 0.154). Resolution 
rate at 6 months was seen to not be statistically significant (p = 1.000). 
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Table 5.5.1 – Resolution of decreased serum Vitamin B12 level in treatment groups 
   
 
Number of patients resolved – n  (% of 
group population) 
Treatment Group 3 Months 6 Months 
Hydroxocobalamin 
Injection 
5 (71.4%) 4 (80.0%) 
Methylcobalamin 
Sublingual 
10 (100%) 8 (80.0%) 
Total 15 (88.2%) 12 (70.6%) 
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Figure 5.5.1 – Illustration of Vitamin B12 levels of each patient at 3 months showing 
treatment groups, red line shows 220 pmol/L level which is considered to be level of 
resolution of lowered Vitamin B12 level 
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Figure 5.5.2 – Illustration of Vitamin B12 levels of each patient at 6 months showing 
treatment groups, red line shows 220 pmol/L level which is considered to be level of 
resolution of lowered Vitamin B12 level 
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5.6 – Neuropathy and symptomatic Vitamin B12 status 
 
Using the Michigan Neuropathy screening Instrument (MNSI) neuropathy is defined operationally: 
- Score of ≥ 7 on patient questionnaire for neuropathic symptoms 
- Score of > 2 on the examination for neuropathic evaluation 
Mean scores for questionnaire for neuropathy evaluation yielded no patients that would be classed 
as neuropathic by the above guidelines at baseline or at the 6 month time period. Mean scores for 
the entire population of 2.09 at baseline (SD 2.11) and 2.20 at 6 month time point (SD 1.85) 
showed no significant difference after treatment (p = 0.535).  
No difference in mean score between the two treatment groups at baseline or at the 6 month time 
point for questionnaire score (p = 0.244 and p = 0.673 respectively) 
Mean scores for examination for neuropathy evaluation yielded 2 patients that would be classed as 
neuropathic by the above guidelines at baseline, both were still classed as displaying neuropathy at 
the 6 month time period. Mean scores for the entire population of 0.94 at baseline (SD 1.73) and 
1.37 at 6 month time point (SD 2.49) and showed no significant difference after treatment (p = 
0.307).  
No difference in mean score between the two treatment groups at baseline or at the 6 month time 
point (p = 0.804 and p = 0.945 respectively) 
 
No difference was seen between the 3 month or 6 month scores for either the questionnaire or the 
examination for either treatment group assessed independently. 
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Table 5.6.1 – Scores for patient questionnaire according to MNSI guidelines 
 
 
 
Table 5.6.2 – Scores for patient examination according to MNSI guidelines 
 
 
 
 
Treatment  
Baseline 
Michigan Score 
6 Month 
Michigan Score 
Δ Michigan 
Score 
Hydroxocobalamin 
Injection 
Mean 1.36 1.83 0.17 
Std. Dev 2.17 2.75 0.29 
N 6 3 3 
Methylcobalamin 
Sublingual 
Mean 2.60 2.06 -0.31 
Std. Dev 2.01 1.70 1.09 
N 10 8 8 
Treatment  
Baseline 
Michigan Score 
6 Month 
Michigan Score 
Δ Michigan 
Score 
Hydroxocobalamin 
Injection 
Mean 1.08 1.30 0.08 
Std. Dev 2.18 2.64 0.38 
N 6 3 3 
Methylcobalamin 
Sublingual 
Mean 0.85 1.62 0.56 
Std. Dev 1.53 2.84 1.32 
N 10 8 8 
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Table 5.6.3 – Number of patients exhibiting neuropathy according to MNSI guidelines 
 
 
 
 
 
 
 
 
 
 
The presence of general fatigue was assessed as a symptom of Vitamin B12 deficiency in patients 
from the study population. There was no significant difference between the number of patients in 
each group who reported the symptom (p = 0.913) 
 
Table 5.6.4 – Number of patients with the symptom of general fatigue in each treatment 
group 
 
 
 
 
 
 
Using logistic regression there was no correlation between serum Vitamin B12 and the presence of 
the symptom of general fatigue in patients from the study population (p = 0.427). 
  
 
Number of patients exhibiting 
neuropathy (% of group population) 
Treatment Group Baseline 6 Month 
Hydroxocobalamin 
Injection 
1 (16.67%) 1 (16.67%) 
Methylcobalamin 
Sublingual 
1 (10.00%) 1 (10.00%) 
Treatment Group 
Number of patients claiming general 
fatigue (% of group population) 
Hydroxocobalamin 
Injection 
4 (57.1%) 
Methylcobalamin 
Sublingual 
6 (60.0%) 
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5.7 – Potential confounding factors  
 
Additional factors of age, ethnicity, gender, healthcare environment, co-treatment with insulin, 
dosage and duration of metformin treatment were assessed for predictability of serum Vitamin B12 
at any time point. All were found to have no effect on any of the serum Vitamin B12 level results or 
the prevalence results at any time point (data not shown). 
 
The factor of dosage of metformin was seen to effect serum Vitamin B12 level at 3 months and 
prevalence of decreased Vitamin B12 status at 3 months (p = 0.012 and p = 0.010 respectively) 
Linear regression modelling of dosage of metformin (mg/day) vs. serum Vitamin B12 level resulted 
in a linear correlation coefficient of -0.640 (p = 0.006) 
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Figure 5.7.1 – Scatter of the suggested relationship between dosage of metformin and serum 
Vitamin B12 level (pmol/L) at 3 month time point 
 
 
 
 
 
 
The dosage of metformin was not found to be correlated to baseline serum Vitamin B12 level or 
serum Vitamin B12 level at the 6 month time point (p = 0.487 and p = 0.728 respectively) 
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Factor of Omeprazole (Losec) usage was found to significantly decrease serum Vitamin B12 level at 
the six month time point (p = 0.041) and was found to increase prevalence of decreased serum 
Vitamin B12 level at the six month time period (p = 0.009) 
Losec treatment increases odds ratio of decreased serum Vitamin B12 status (<220 pmol/L) at the 
six month time period by a factor of 4.000 
 
Table 5.7.1 – Effect of Losec treatment on mean serum Vitamin B12 level (pmol/) of study 
population 
 Mean serum Vitamin B12 level (pmol/L)(SD) 
 Baseline 3 month 6 month 
Losec treatment 
(n = 5) 
158.80 (42.81) 339.80 (130.19) 222.50 (56.72) 
No Losec treatment 
(n = 12) 
172.92 (38.35) 361.83 (121.63) 276.09 (42.99) 
 
 
 
Table 5.7.2 – Effect of Losec treatment on prevalence of decreased serum Vitamin B12 level 
of study population 
 
Prevalence of decreased serum Vitamin B12 
level (<220 pmol/L) (n) (% of population) 
 3 month 6 month 
Losec treatment 1 (20%) 3 (75%) 
No Losec 
treatment 
1 (8%) 0 (0%) 
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6.0 Discussion  
6.1 – Prevalence of lowered serum Vitamin B12 level 
 
Although there are recommendations for the annual screening of Vitamin B12 status in patients with 
type 2 diabetes on long term metformin treatment; it has been observed in this audit that this is not 
a common practice. The front line usage of metformin as a therapeutic agent was evident from the 
review of patients visiting the Diabetes Clinic at Wellington Regional Hospital (Table 4.1.3), 
suggesting a high number of patients potentially at risk of metformin associated Vitamin B12 
deficiency. American Diabetes Association (ADA) guidelines for 2013 recommend the 
commencement of metformin as the initial pharmacological agent for type 2 diabetes when there 
are no contraindications (Amer Diabet, 2013). New Zealand Ministry of Health Primary Care 
Handbook 2012 recommends metformin as a primary intervention agent for glycaemic control 
once lifestyle modifications have been deemed ineffective (New Zealand Primary Care Handbook 
2012., 2012).  The National Health and Medical Research Council (NHMRC) for the Australian 
Government encourage the use of metformin as a safe and effective treatment of patients with type 
2 diabetes (Colaguiru, 2009). With these recommendations in mind it is imperative to fully 
investigate any interactions that a pharmaceutical agent may have in order to prevent wide spread 
impairment.  
There are several factors that may be relevant in the comparison of populations from the 
two different healthcare environment populations studied. Patients who are seen in the Diabetes 
Clinic (secondary healthcare) are often more complex, with associated comorbidities or diabetes 
complications, and often having poor glycaemic control resulting in the referral to a specialist 
service. This may lead to a higher level of Vitamin B12 deficiency owing to potential factors such as 
poor diet and maintenance of health. It is also quite possible that once referred to specialist care the 
patients are exposed to a more comprehensive health care environment that will consider and 
address factors that may be over looked in a primary health care setting. However these factors did 
not appear to have a significant influence on serum Vitamin B12 level,  there was no difference 
between primary and secondary care. Age was seen to be significantly different between the two 
population groups, with the secondary care group being older (Table 4.1.1). Increasing age has been 
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associated with lower Vitamin B12 status in some patients (Green et al., 2005) and may cause 
confounding interaction with some of the comparisons between the population groups.  
The screening in both Primary Health Providers as well as the Diabetes Clinic shows that 
there is a limited amount of Vitamin B12 monitoring occurring with over 20% of patients reviewed 
through the Diabetes Clinic having no reported serum Vitamin B12 (Figure 4.1.5). Only one of the 
four medical centres approached for recruitment had a regular serum Vitamin B12 screening 
program for patients with type 2 diabetes who are taking metformin.  Medsafe guidelines for the 
treatment of patients with Type 2 Diabetes with metformin state that there is an investigated 
association of Vitamin B12 deficiency with long term treatment (Medsafe, 2009). Whether this is 
being regularly considered by primary health providers is not known. ADA guidelines only 
recommend Vitamin B12 testing in two scenarios; the diagnosis of patients who exhibit neuropathy, 
where prolonged metformin use is mentioned as a contributing factor, and in patients with type 1 
diabetes who exhibit signs and symptoms of potential additional autoimmune pathogenesis (Amer 
Diabet, 2013).  These recommendations may result in patients missing screening owing to delayed 
onset of neuropathic symptoms in patients with type 2 diabetes taking metformin. NZ Primary 
Care Handbook has no mention of potential Vitamin B12 deficiency associated with metformin use 
(New Zealand Primary Care Handbook 2012., 2012). The Australian National Evidence Based 
Guideline for Blood Glucose Control in Type 2 Diabetes released by the NHMRC does not 
mention potential vitamin B12 deficiency as a result of metformin usage (Colaguiru, 2009).  
The overall level of prevalence that was observed for impaired Vitamin B12 (serum Vitamin 
B12 <220 pmol/L) of 19.56% of patients (Figure 4.1.6) is similar to results from other studies 
(Mazokopakis & Starakis, 2012; Reinstatler et al., 2012).  The lack of observable difference 
between both serum Vitamin B12 level and prevalence of decreased Vitamin status between the 
two investigated populations (Table 4.1.6) may be due to an absence of regular screening thus no 
difference in health care environment is influential on such values. Previous reports have shown that 
long term treatment of patients with Type 2 Diabetes with metformin can result in a lowered level 
of Vitamin B12 in anywhere from 5 – 22.6 % of the treated population(de Groot-Kamphuis et al., 
2013) with one study claiming a 36.8% prevalence rate (Nervo et al., 2011). The vast range of 
prevalence rates are observed in countries of varying economic status. This may suggest that the 
decreased Vitamin B12 status is therefore more attributed to other factors, such as some form of 
dietary impairment, as opposed to metformin interactions. The Reinstatler et al study was based on 
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a population within the United States and reported a biochemical Vitamin B12 deficiency in only 
5.8% of patients with type 2 diabetes taking metformin compared to only 2.4% of patients with 
type 2 diabetes who were not taking metformin. However there was also a reported rate of 3.3% 
prevalence of deficient biochemical Vitamin B12 in patients who did not have type 2 diabetes and 
who were not taking metformin. This may suggest that while the prevalence of metformin 
associated deficiency is higher and statistically significant there are additional factors which may 
influence the prevalence.  
This is in stark contrast to the Nervo et al study which was based on a population in Brazil. 
While the range for deficiency in this study was slightly higher (250 pmol/L vs 220 pmol/L) the 
prevalence of decreased serum B12 in the Brazilian population was seen to be at a level of 36.8% of 
assessed patients. Differences between the two aforementioned studies are also seen in the effect of 
vitamin supplementation in the population. While supplementation with vitamin B12 in the study 
based on an American population did not result in significant alteration to prevalence, the Brazilian 
based population suggested an increase in Vitamin B12 intake is positively correlated to serum 
Vitamin B12 status. This supports the notion that the impairment is linked more closely to 
malnutrition of Vitamin B12 in the diet of the populations.  
The distribution of serum Vitamin B12 level obtained in the screening was not that of 
normal distribution, but rather skewed towards the lower serum Vitamin B12 level with a tail to 
the higher levels (Figure 4.1.3). This in itself may suggest an increased risk of serum Vitamin B12 
level lowering or may suggest a number of patients taking supplementary Vitamin B12 that was not 
noted in the screening phase. The peak of the distribution was seen to fall lower than would be 
expected of normal distribution and only slightly higher than the 220 pmol/L level of lowered 
Vitamin B12 status.  According to the National Health and Nutrition Examination Survey (Second 
National Report on Biochemical Indicators of Diet and Nutrition in the U.S. Population 2012, 2012) carried 
out in America between the years 2003 to 2006, the average serum Vitamin B12 level in the study 
population was 500 pg/mL (approximately 370 pmol/L). This value is seen to be higher than the 
mean serum Vitamin B12 level found in this study (354.77 pmol/L) (Table 4.1.4). As the survey 
was carried out on a study population intended to be a representative of national standards it can 
therefore be argued that the treatment of metformin, or arguably the presence of type 2 diabetes, in 
the population of this study did not have a significant effect on serum Vitamin B12 level. 
Furthermore prevalence data from the same survey suggests that there is a 2% prevalence of 
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Vitamin B12 deficiency (defined as B12 < 148pmol/L) in the national population. Applying the 
same standard for the deficient status to this study the prevalence would be 4.7%. Although 
metformin may be a factor in this it cannot be concluded that this is due solely to the metformin 
treatment, or whether type 2 diabetes is a more pronounced influence on serum Vitamin B12 level, 
or dietary/supplement factors (Obeid et al., 2013). 
Unfortunately there is scarce literature on Vitamin B12 status in a general population in 
New Zealand. One study which aimed to evaluate the Vitamin B12 status of an elderly population 
in New Zealand (age >65) claimed there is a 35.54% prevalence of lowered serum Vitamin B12 
level (<221 pmol/L) (Green et al., 2005). This level reflects the much researched association of 
age and decreased Vitamin B12 status, and suggests that the levels that were shown in this study 
may not be solely metformin associated but reflect more on the age of the patients involved. The 
prevalence of lowered serum Vitamin B12 level (<220 pmol/L) in our study in the elderly 
population (age ≥ 65) was compared with the population in the Green et al. study. It was observed 
that prevalence of decreased serum Vitamin B12 status in metformin treated patients in our study 
was lower than those in the Green et al study. This comparison must be interpreted with caution as 
there are other factors that may affect the serum Vitamin B12 of these patients which were not 
addressed in this study (diet, drug interactions etc.). Furthermore as the patients recruited into the 
Green et al study were non-institutionalized there may have been a level of malnutrition in regards 
to nutritional intake as has been observed in such populations (McElnay et al., 2012). However it is 
interesting to note that our sample population had a better Vitamin B12 status than that of a 
population without diabetes type 2 or metformin treatment 
 While there are some apparent reductions in Vitamin B12 serum as a result of metformin 
treatment, the natural presence of lowered Vitamin B12 levels in older populations and prevalence 
of deficiency in such patients may account for a large proportion of these cases. An analysis 
published in the American society of nutrition highlights this (Allen, 2009). The argument is made 
that, according to the national health and nutrition examination survey, the presence of Vitamin 
B12 deficiency is no higher in the tested population of metformin treated patients who have type 2 
diabetes than in a standard population. Much like the presence of comparable rates of Vitamin B12 
deficiency (< 148 pmol/L) the comparison between levels deemed to be borderline (148 – 221 
pmol/L) bring about startling similarities. Evidence is cited that up to 20% of people assessed are 
within the range of “borderline” serum Vitamin B12 level. This figure is higher than that of the 
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population in this study (19.75%) (Figure 4.1.6). Of notable mention is the trend towards decreased 
serum Vitamin B12 in this study in patients taking metformin, a large portion of the population is 
seen to be located just above the cut off for Vitamin B12 deficiency and thus may still be at risk 
(<220 pmol/L) (Figure 4.1.3). 
 
6.1.1 – metformin Dosage 
The analysis of dosage of metformin on the serum Vitamin B12 level has shown results supported by 
previous research (de Groot-Kamphuis et al., 2013). An increase in the dosage of metformin 
correlates with an apparent decrease in serum Vitamin B12 (Figure 4.2.3). Linear regression suggests 
that for every milligram increase in metformin dosage, serum Vitamin B12 level are lowered by 
0.040 pmol/L; in common dosage quantities this would suggest a dosage difference of 1000mg 
would result in an expected linear reduction of serum Vitamin B12 by approximately 40 pmol/L. 
This is evident in categorical comparison of metformin dosage (Figure 4.2.4). However it is not 
known by these results how this deficit would accumulate over time.  
The mechanism of metformin inhibition of absorption is not fully understood. The current 
theory of inhibition is based on interference with intrinsic factor binding in the gut. It would be 
assumed that an increase in concentration of the inhibiting substance (metformin) would result in an 
increase in inhibition of said absorption. As metformin is excreted unchanged in urine with an 
elimination half-life of approximately 5 hours (Graham et al., 2011) it would be logical for the 
relationship between metformin and Vitamin B12 malabsorption to be somewhat linear. The daily 
intake of Vitamin B12 in the body, approximately 2.4 micrograms, is much lower than natural body 
stores, of close to 2500 micrograms (Mazokopakis & Starakis, 2012). Thus even with partial 
malabsorption caused by an external agent the effect would take a long period of time to develop 
clinical important deficiency. The apparent association between increased dosage of metformin and 
decreased serum Vitamin B12 level was observed in this study. Through linear regression there is a 
significant decrease of serum Vitamin B12 with increase in dosages (Figure 4.2.3); this can also be 
seen in a categorical dosage comparison (Figure 4.2.4). The reduction in serum Vitamin B12 level 
translates to an increase in prevalence of decreased Vitamin B12 status (through logistic regression); 
however no specific difference was seen between any two of the categories of metformin dosage. 
This may be due to the reasonably low populations in the groups of metformin dosages as on 
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appearance the prevalence levels seem to increase strongly with an increase in dosage of metformin. 
Odds ratio analysis exhibits this trend, showing increases in the risk rate of lowered serum Vitamin 
B12 level as doses of metformin are increased, with the most significant increase seen in the 
increase of dosage from below 1000 mg/day to between 1000 and 1500 mg/day (Table 4.2.4). The 
values for this increased odds ratio did not match that of a previous study (de Groot-Kamphuis et 
al., 2013) which claimed a value of 1.081 per 100 mg increase in daily metformin however this is 
based on a level of <150 pmol/L for decreased serum Vitamin B12 status.  
A correlation was observed between the dosage of metformin prescribed and age (Figure 
4.5.3). This correlation suggests that with an increase in age, a decrease in dosage of metformin is 
observed. This may be due to several different clinical reasons; as patients age treatment focus may 
tend to shift from preventing long term hyperglycaemic complications to preventing short term 
hypoglycaemic episodes. While metformin does not cause hypoglycaemia it may influence an 
episode in patients taking insulin. Renal impairment results in reduced excretion of metformin and 
thus reducing dosages once renal function begins to decline is common practice. Renal impairment 
is common in the elderly and is further increased with the development of diabetic nephropathy. 
The dose of metformin is often maximized in patients who are nearing the point of requiring insulin 
therapy; however as the additional benefits of doses greater than 2000 mg per day is marginal, after 
the introduction of insulin the dose is often reduced from 3000 mg per day to 2000 mg per day to 
minimize side effects. Adjustment for this factor into the regression model of dosage of metformin 
and serum Vitamin B12 level did not alter the significance of the model however. 
 
6.1.2 – Duration of metformin Treatment 
Duration of metformin treatment influences serum Vitamin B12 level. Due to the large natural 
stores of Vitamin B12 in the human body of around 2500 µg, and the reasonably low daily intake 
(≈2.4 µg) it is thought that a long period of malabsorption is required to cause clinically important 
Vitamin B12 deficiency (Mazokopakis & Starakis, 2012). The time point at which metformin use 
becomes a factor in the risk of Vitamin B12 deficiency and some form of clinical presentation is 
commonly thought to be between 5 – 10 years of treatment (Mazokopakis & Starakis, 2012). 
However there have been observations made on the effect of metformin on Vitamin B12 from as 
early as one year from commencement of treatment (Chen, 2012). The results from this study have 
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shown that there is an apparent but not statistically significant correlation between duration of 
metformin treatment and both serum Vitamin B12 level and prevalence of decreased Vitamin B12 
status (Figure 4.3.4). Post-hoc analysis highlighted several duration ranges which were statistically 
different, the Pearsons correlation showed significance of duration of metformin treatment (p = 
0.044). Durations of treatment of above nine years started to suggest linear decreases in serum 
Vitamin B12 level however with low numbers in some categories these changes were not 
statistically significant. A larger population study may help to clarify this relationship. As stated 
previously metformin excreted unchanged in the urine and has a reasonably short half-life within 
the body. Therefore current views on metformin interference with intrinsic factor binding leading 
to malabsorption of cobalamin would be a cumulative process as internal body stores are used and 
not replaced. Furthermore as the interaction between metformin and the cubulin receptor is said to 
work through competitive inhibition there would still be some cobalamin being absorbed 
dependent on the level of dietary intake.  
A correlation between duration of metformin use and serum Vitamin B12 is observed in 
this study which supports previous findings of association; however the relationship between the 
two variables becomes more complex when confounding variables are considered. While the 
duration of metformin treatment was seen to correlate with serum Vitamin B12 level, it was also 
seen to correlate with age of the patient (Figure 4.5.4). This follows from logical reasoning that the 
longer a patient is on metformin, the older the patient is likely to be, however it creates a 
confounding effect on our analysis of the influence of the long term impacts metformin use may 
have on serum Vitamin B12. The associations drawn from this paper which are thought to be 
related to duration of metformin treatment may simply be the observation of the age related 
malabsorption that has been observed in other studies. This was tested with age adjustment of the 
regression model for the relationship between duration of metformin treatment and serum Vitamin 
B12 level. This resulted in a reduction of the significance of duration of metformin to an 
insignificant level (p = 0.051).  
It is important to note a limitation of this study  was the ability to collect accurate data for 
duration of metformin treatment. The data were collected as the first documentation of metformin 
treatment in an individual patient according to available databases. For patients in a primary health 
care environment this was the database of the medical centre they were currently enrolled in, for 
secondary health care patients it was the Diabetes Clinic database. Neither of these are robust 
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sources of information for this purpose. While electronic patient transfer aims to maintain medical 
notes of patients moving from one medical centre to the next, there is a possibility of incomplete 
records being used. Furthermore information regarding metformin duration obtained from diabetes 
clinic database is limited to the patient attendance to a secondary health service at which time 
metformin use was noted. This has likely resulted in many patients having much lower reported 
metformin duration than is actually the case and therefore caution is advised when interpreting the 
results and correlations made.  
 
 6.1.3 – Ethnicity 
One of the unique aspects to this study is the consideration of ethnic differences in the New Zealand 
population, a factor that has not yet been explored in previous literature. The method of analysis 
between ethnic groups was based on grouping of the New Zealand Ministry of Health ethnic 
categories. This allowed a more statistically viable assessment of the effect of ethnicity on serum 
Vitamin B12 level. All categories in which there were more than 15 individuals who identified to be 
within the category were maintained as separate groups. This resulted in the five groups as defined 
in the results. All other individuals who identified as other categories were combined in a singular 
“Other” category (Table 4.4.1). The significant differences between the ethnic groups were seen to 
not only be in the serum Vitamin B12 level but also in the age variable where the Other European 
population was significantly older than all other population groups. Higher mean serum Vitamin 
B12 level was seen in NZ Maori and Samoan populations compared to the remaining groups (Figure 
4.4.1). However this did not translate to a significant decrease in prevalence of Vitamin B12 
deficiency. This may be due to small numbers of, particularly in the Samoan group, in the deficient 
category and a larger sample size may have helped clarify this.  
The cause for a higher mean Vitamin B12 level in NZ Maori and Samoan populations 
compared to both NZ Europeans and Other European populations is not easy to distinguish. 
Previous research into micronutrient levels in different ethnicities did however show similar results 
(Hinds, Johnson, Webb, & Graham, 2011). Hinds et al has shown evidence that an “American 
Black” population has a significantly higher mean Vitamin B12 level than their “American White” 
counterparts. This may suggest that there is a genetic or lifestyle factor that predisposes people of 
Caucasian decent from yielding lower Vitamin B12 levels that those of other ethnical backgrounds. 
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Conversely non-European individuals may not be relatively protected from Vitamin B12 deficiency, 
again either through dietary or genetic factors.  
 For example a potential explanation for the difference in mean Vitamin B12 levels between 
the mentioned ethnicities may be elucidated from the 2008/2009 New Zealand Adult Nutrition 
Survey. This data shows that levels of Vitamin B12 consumption via the dietary groups of red meat 
and seafood are higher in the Maori population than that in the NZ European population (A Focus on 
Nutrition: Key findings of the 2008/09 New Zealand Adult Nutrition Survey, 2011). A similar pattern of 
dietary preference can be seen in the Pacific population, of which the Samoan ethnic group is part 
of, in which a higher proportion of Vitamin B12 is derived from fish and seafood compared to that 
of NZ Europeans. Vitamin B12 is at a much higher concentration in meat, fish, and shellfish as 
opposed to milk, which is the primary source for European populations (9.4 μg/100g, 
9.9μg/100g, 52.4μg/100g and 0.4μg/100g respectively) (Watanabe, Yabuta, Tanioka, & Bito, 
2013). Thus greater intake may explain the higher levels of Vitamin B12 in Maori and Samoan 
populations. The inclusion of some form of dietary assessment such as a food frequency 
questionnaire with the specific food items may have provided more insight into this. 
  
6.1.5 – Future Research 
In order to better understand the role that ethnicity may play on serum Vitamin B12 level of New 
Zealand patients with Type 2 Diabetes being treated with metformin a greater population size 
should be considered to ensure comprehensive demographic consideration. With known predictor 
variables such as age being influential in this analysis it is recommended that a younger population 
group be saturated to allow comparative analysis. More thorough investigation needs to be carried 
out on the variable of ethnicity on both serum Vitamin B12 and prevalence of decreased Vitamin 
B12 status. This should consider the factor of dietary intake as aforementioned in order to assess not 
only ethnic dietary differences but also age related nutritional comparisons. The use of a healthy 
control population, and/or a group without diabetes who are taking metformin for another reason, 
such as woman with polycystic ovarian syndrome, to assess the effects of metformin on a population 
of patients who do not have type 2 diabetes would further lend information towards the 
understanding of the potential interactions of metformin and Vitamin B12 absorption.  
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6.1.6 – Concluding statements 
The results of the prevalence aspect of this research has given new insight into both the prevalence 
of Vitamin B12 deficiency in New Zealand as well as suggested factors that may impact the 
likelihood of a patient developing said deficiency.  
While correlations have been seen between factors of metformin treatment (dosage and 
duration), it is not clear whether the factor of metformin treatment is the most influential in 
regards to a decreased Vitamin B12 status in a New Zealand population base. Prevalence of 
decreased serum Vitamin B12 level was comparative to populations in population of similar 
economic development where there was no metformin treatment present. Coupled with the high 
prevalence of age related vitamin malabsorption, and high levels of elderly patients in this study, it 
is difficult to ascertain that the observed deficiency was significantly caused by metformin 
interaction without an appropriate control population, or a prospective randomised controlled 
design. The role of ethnicity in Vitamin B12 status is important in the New Zealand population with 
marked differences between the ethnic groups. Whether this is related to genetic, lifestyle or 
dietary factors is uncertain.  
 Much evidence has been put forth to suggest that the use of serum Vitamin B12 level as a 
measure of physiological Vitamin B12 functionality is insufficient, thus proposing that any 
observable serum Vitamin B12 deficiency that may be linked to metformin treatment may not 
necessarily lead to clinical implications.  This study further supports the previous findings of 
prevalence rates of serum Vitamin B12 deficiency but does not provide insight into the outcomes of 
such an effect through assessment of any markers of Vitamin B12 functionality.  
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6.2 – Randomized Control Trial 
 
The randomised controlled study has given evidence that the treatment of patients with 
decreased serum Vitamin B12 level with both Hydroxocobalamin injections and Methylcobalamin 
sublingual supplementation is effective in correcting an impaired Vitamin B12 status. Both 
treatments resulted in significant improvements in not only serum Vitamin B12 level (Table 5.3.1) 
but also showed marked decreases in prevalence of low Vitamin B12 levels (Table 5.5.1). While 
both treatments were effective in the management of decreased Vitamin B12 levels, there were 
significant differences in the level of therapeutic impact in both short and long term instances (Figure 
5.3.2).  
 
The current treatment method of choice for Vitamin B12 deficiency is intra muscular 
Hydroxocobalamin injections. These have been shown to improve both biochemical markers for 
B12 deficiency and also improve physiological functions of Vitamin B12 deficiency (Castelli & 
Kragie, 2013; Glass, Skeggs, & Lee, 1966; Hvas & Nexo, 2006; M. R. Turner & Talbot, 2009). 
The administration of a single dose of 1mg Hydroxocobalamin was seen to correct serum Vitamin 
B12 status in a majority of the patients treated in this study. Furthermore the corrected levels were 
seen to remain in the normal range for up to 6 months post-treatment. This long term effect of 
Hydroxocobalamin treatment is thought to be due to the increased retention of the cobalamin form 
compared to other B12 vitamers.  
The current treatment protocol for Vitamin B12 deficiency dictates that a loading period of 
Hydroxocobalamin should be used in order to raise baseline levels before a periodic maintenance 
regimen should be initialised. One study suggests a daily 1mg administration of Hydroxocobalamin 
daily for one week followed by 1 mg once weekly for 4 weeks, subsequent maintenance of B12 is 
achieved through 1 mg administration every 2-3 months (Mazokopakis & Starakis, 2012). While 
this regimen would lead to an increased rate of Vitamin B12 correction, results from our study 
suggest that this protocol would lead to over correction in decreased levels of Vitamin B12 caused 
by metformin treatment. Evidence for this can be seen not only in the success of treatment with a 
single Hydroxocobalamin treatment in 71.4% of patients, but also in the maintenance of the 
resolved Vitamin B12 levels in all but one of the patients at the 6 month time period (Table 5.5.1). 
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There is little information about the possible consequences of elevated serum Vitamin B12 level, 
and the masking of other biomarkers is possible with excessive Vitamin B12 in the blood.   
 
6.2.1 – Treatment factors 
Methylcobalamin treatment exhibited a quicker increase in serum Vitamin B12 level (Table 5.3.1). 
This steeper increase in blood levels of B12 may be caused by several factors in the treatment; the 
mode of treatment, the increased dosage of B12 as compared to the comparative treatment group, 
and finally the binding affinity and clearance of Methylcobalamin compared to Hydroxocobalamin.  
The use of sublingual delivery is a growing trend in vitamin supplementation. The method 
evades the potentially damaging first pass of the liver and allows a more direct absorptive path into 
the capillaries and thus the rest of the blood. This is of higher importance in the case of metformin 
induced Vitamin B12 malabsorption as the proposed method of interaction of metformin is that of 
interference with intrinsic factor absorption of Vitamin B12 during digestion (Bauman et al., 2000). 
The use of sublingual treatment therefore would evade such a mechanism and should allow for 
direct Vitamin B12 absorption. The dosage regimen for the sublingual treatment group involved a 
single 1000mcg sublingual tablet taken once a day for 30 days. This is a higher dosage than that of 
the single 1mg injection administered to the other treatment group and could explain a much higher 
treatment response. Although the response is markedly less than that of the Hydroxocobalamin 
when considering increase in serum Vitamin B12 level pmol/mcg of treatment provided. 
Methylcobalamin is one of the physiologically active forms of cobalamin; there is evidence to 
suggest that the uptake cobalamin in this form has a different affinity than that of Hydroxocobalamin 
due to binding affinity of transcobalamin (Gherasim et al., 2013). 
The assessment of sublingual treatment as a comparable treatment to oral supplementation 
has resulted in corrections of serum and functional marker of Vitamin B12 status (Yazaki et al., 
2006). Methylcobalamin has been shown to be equally as effective in sublingual treatment as in oral 
administration in an elderly population (age 50 – 80). Results from this study support the 
observation of increased serum Vitamin B12 level with treatment of Methylcobalamin however it 
cannot be asserted whether there was an increase in the physiological effect of Vitamin B12 as 
functional biomarkers were not assessed. Intestinal malabsorption of Vitamin B12 in elderly 
population may mimic the malabsorption of Vitamin B12 in patients being treated with metformin 
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due to the phase of absorption and interaction of intrinsic factors that are influenced (Bauman et al., 
2000; Yazaki et al., 2006); therefore there may be physiological improvement in an impaired 
functionality of Vitamin B12 deficiency caused by metformin treatment with Methylcobalamin 
sublingual supplementation. Other administration routes for the treatment of Vitamin B12 
deficiency have shown effective increases in of serum Vitamin B12 level which would avoid the oral 
route of administration such as intranasal administration (Lonterman et al., 2000). Again such 
routes are seen to increase serum Vitamin B12 level but an absence of physiological functionally 
testing has not addressed the issue of the translation ability of serum levels in diagnosis of Vitamin 
B12 deficiency.  
 
6.2.2 – Long term benefits 
The differences in the long term effects of the two treatment groups may be attributed to the 
different clearance and excretion properties of the two cobalamin vitamers (Table 5.4.1). Research 
into the clearance of Hydroxocobalamin has been scarce since the 1960’s when the drug was 
extensively investigated as a replacement to cyanocobalamin as a treatment option for patients 
suffering from pernicious anaemia and Vitamin B12 deficiencies. In a detailed assessment of 
Hydroxocobalamin clearance following both 500mcg and 1000mcg injections the levels of serum 
Vitamin B12 were analysed at 5, 24, 48, 72 hour post injection time points, as well as at 1, 2, 3, 
and 4 week post injection time points (Hertz, Kristensen, & Hoff-Jorgensen, 1964).  These data 
highlighted a significant short term increase in B12 which decreases significantly by 72 hours. 
Measurements of urinary excretion of B12 found that 27% of the 1000mcg dose of Vitamin B12 
was removed from the body within the first 72 hour period.  According to this pattern Vitamin B12 
retention, the time points for measurements of Vitamin B12 for patients in this study will have 
missed the initial peak level of serum Vitamin B12 level. While this may not be ideal for complete 
analysis of the treatment protocol, it may be argued that the initial increase of Vitamin B12 in the 
blood does not provide extensive therapeutic advantage to the patient as the clearance is rapid.  
Further study into the mechanism of Hydroxocobalamin has shown a high affinity of binding 
to liver cells which have been identified as a location of high Vitamin B12 storage. Vitamin B12 
bound to transcobalamin II is rapidly cleared from plasma and preferentially distributed to hepatic 
parenchymal cells where it remains as an active coenzyme. This transport of cobalamin from the 
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blood and into an intracellular storage state may explain the large discrepancy between the 
measured amount cobalamin excretion and the serum Vitamin B12 level after injection with 
Hydroxocobalamin. It has also been suggested that there is preferential movement of cobalamin to 
liver storage by TC-II in the presence of serum albumin when the cobalamin is in the form of 
Hydroxocobalamin (Begley, Colligan, & Chu, 1993). This may suggest a higher preferential storage 
and slow usage of Vitamin B12 in the Hydroxocobalamin form, this would also aid in explanation of 
the lower response peak of Vitamin B12 in the serum but a longer effect tail as the vitamin is used. 
This is comparative to the rapid decline in serum Vitamin B12 level in the patients assigned to the 
Methylcobalamin sublingual supplement group. Whilst receiving treatment, over the first 3 
months, the results showed large increases in serum Vitamin B12, all patients were resolved at the 
3 month time point. However the retention of this treatment effect was much lower than that of 
Hydroxocobalamin (Table 5.4.2). This may be due to the specificity of the serum Vitamin B12 assay 
which does not distinguish between bound and unbound Vitamin B12 it may be that the high 
increase in serum levels is due to unbound, and non-functional free Vitamin B12, which seem to be 
rapidly removed from the blood once treatment is ceased. This has resulted in two patients 
returning to a deficient Vitamin B12 status (<220 pmol/L) by the end of 3 months of observation 
(Table5.5.2). 
 
6.2.3 – Cellular considerations 
Cellular uptake of cobalamin requires the presence of transcobalamin as the binding of the complex 
to the transcobalamin receptor is structurally specific. Unbound transcobalamin (apo-
transcobalamin) in the blood can bind to free Vitamin B12 molecules for transport of the molecule 
to cells that require its functionality. Free Vitamin B12 in the blood is thought to be not internalized 
due to the absence of an uptake mechanism that does not rely on some form of transcobalamin 
binding (Quadros, 2010). Serum Vitamin B12 assays measure the level of total Vitamin B12 in the 
blood, both bound and unbound forms, free forms, and therefore may not represent the measure of 
functionally available Vitamin B12 in the body (Hvas & Nexo, 2006). The presence of circulating 
haptocorrin in the blood may bind free forms of Vitamin B12 thus making it inaccessible for 
transcobalamin binding and cellular uptake. Supplementation of Vitamin B12 in patients with 
Vitamin B12 deficiency has been seen to increase both serum levels and functional biomarkers, total 
homocysteine, of Vitamin B12 activity (Deshmukh et al., 2010) in certain populations while only 
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significantly improving serum Vitamin B12 in other populations (Favrat et al., 2011). This may be 
due to the main causative factor of Vitamin B12 in each of the population structures, malnutrition 
vs. malabsorption. Treatment of decreased Vitamin B12 in elderly patient populations with oral 
supplementation has been to increase both serum Vitamin B12 and specific holotranscobalamin 
levels in deficient patients (Albers et al., 2012) suggesting that impairment in absorption of Vitamin 
B12 can be corrected by increased dietary supplementation of the vitamin.  
It has been suggested that metformin increases liver preferential storage of Vitamin B12 
(Greibe, Miller, et al., 2013), coupled with the higher affinity of Hydroxocobalamin to bind to 
hepatic parenchymal cells via preferential trafficking (Begley et al., 1993), may suggest that the 
decreased serum Vitamin B12 level response to Hydroxocobalamin compared to Methylcobalamin 
is due to increased hepatic storage of the vitamin as opposed to a more deficient state or lower total 
Vitamin B12 in the body.   
 
 6.2.4 – Potential Confounding Factors 
There were several interactions noted during the study period that were seen to have a potential 
influence on the outcome measures: 
Final decreased Vitamin B12 status prevalence in this study was seen to be significantly 
correlated to the co-treatment of patients with Omeprazole; an increased rate of relapse into 
cobalamin deficient states was seen in patients who were also treated with the drug. Research into 
the use of proton pump inhibitors (such as Omeprazole) and their effect on cobalamin levels have 
yielded mixed results (Marcuard, Albernaz, & Khazanie, 1994; Schenk, Festen, Kuipers, 
Klinkenberg-Knol, & Meuwissen, 1996).  
It is proposed that the use of PPI decreases the ability of Vitamin B12 cleavage from dietary 
proteins and thus inhibiting the facilitation of intrinsic factor binding (Bradford & Taylor, 1999). 
While some studies suggest direct correlation between proton pump inhibitors (PPIs) and a 
decreased Vitamin B12 state (Hirschowitz, Worthington, & Mohnen, 2008) these results are not 
limited to interactions with the administration of the PPIs but suggest an unobserved further 
interaction to cause the deficient state.  
  
 
123 
 
Common conclusions are drawn that may suggest that the combination of old age and 
treatment with PPIs may have a synergistic  effect on reducing absorption of Vitamin B12 but the 
sole interaction of PPI does not influence this enough to consider it as a separately contributing 
factor. Results from this intervention study might suggest a more direct correlation between serum 
Vitamin B12 and PPI treatment. This interaction was only observed after some form of intervention 
and Vitamin B12 supplementation and was not seen to correlate to baseline Vitamin B12 levels or 
prevalence of decreased Vitamin B12 status.  
Such a selective interaction is unusual in this study as both the treatment options provided 
the therapeutic administration of Vitamin B12 to the blood without passage through the gut 
absorptive pathway which is the location of PPI interaction with malabsorption (Bradford & Taylor, 
1999). This would suggest that the patients exhibiting a deficient state at the 6 month time period 
not only have very low retention of introduced Vitamin B12, but also may suggest that the effect of 
PPI treatment may have effects on serum cobalamin levels and not just malabsorption in the gut. 
While this is an untested theory it has been observed in this study that all three of the patients that 
were in lowered Vitamin B12 status at the end of the 6 month time point were also being treated 
with PPIs, and no patients not being treated with PPIs were in such a state at the said time point. 
Furthermore at the 3 month time point, of the two patients that were found to have not been 
resolved of a decreased Vitamin B12 status one was being treated with PPIs, the other was a strict 
vegetarian. A much larger study, with a factorial design including PPI use would be required to 
specifically test these hypotheses.  
 
Only one patient was still in a deficient Vitamin B12 state after an initial and 3 month treatment. 
While the patient made significant improvement in serum Vitamin B12 level after each of the 
treatments (Hydroxocobalamin injection) it is thought that a combination of a low baseline serum 
Vitamin B12 level (80 pmol/L, the lowest of the study population) and strict vegetarianism were to 
be attributed to the lack of Vitamin B12 resolution. This case further raises the issue of synergistic 
effects of numerous factors leading to a deficient state. In can be argued that it was the lack of 
dietary intake of Vitamin B12 by the patient that may have contributed largely to the development 
of a decreased Vitamin B12 status; not helped by some form of malabsorption caused by metformin 
treatment.  
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No significant symptoms of Vitamin B12 deficiency were observed in the study population through 
analysis of symptomatic assessment (Michigan Neuropathy Screening Instrument) (Table 5.6.3). Of 
the study population only one patient from each group was seen to meet the criteria for neuropathy 
(Al-Geffari, 2012), of which one of the two had previously documented and treatment of diabetic 
neuropathy. The consideration of the symptom of general fatigue was difficult to assess as while 
there was a high number of patients claiming to experience the symptom (Table 5.6.4) there was no 
specific correlation with the presence of the symptom and serum Vitamin B12 level. The difficulty 
is whether the qualitative measurement of general fatigue is applicable in a population seen to be of 
an older age with type 2 diabetes. The potential for additional factors affecting the outcome of this 
is high and there may be no interaction with metformin treatment on the presence or absence of 
such a symptom. 
 
6.2.5 – Future Research 
Further study should be aimed at correctly assessing the presence of an impaired state of Vitamin 
B12 in patients being treated with metformin to determine if the apparent deficiency in serum 
levels is functionally relevant. This has been shown to be viable through assessment of MMA and 
tHcys levels. Investigation into the retention of free cobalamin in the blood compared to that of 
intestinally ingested cobalamin will aid in the understanding of the efficacy of sublingual treatment 
against oral medications. Further exploration of retention dependent on the form of cobalamin 
administered may allow for a better understanding of the potential preferential trafficking of 
different vitamers to the storage organs such as the liver. 
Assessment of additional time points may provide a more concise picture of the action of the 
treatments and capture an alternate peak shape which may have passed before the first time point at 
three months. Similarly a longer observation period post treatment would allow more investigation 
into the retention and excretion of the different cobalamin forms and observation of return to 
baseline levels of Vitamin B12 levels of each patient. As evidence from this study has shown, the 
rate of decrease of serum Vitamin B12 post treatment differs significantly between the treatment 
options (Table 5.4.2) and would be of interest in further examination.  
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6.2.6 – Concluding statements 
The evidence from this study has shown that decreased serum Vitamin B12 level in patients with 
type 2 diabetes who are exposed to long term treatment of metformin can be alleviated through 
treatment with either Hydroxocobalamin injections or Methylcobalamin sublingual supplements. 
There is an apparent difference in the mode and shape of treatment effect between the treatment 
groups however and this may lead to preferred treatment through one option as opposed to the 
other. While the sublingual treatment showed rapid increase in serum Vitamin B12 level in a short 
period of time, the benefit of the treatment was seen to decrease rapidly once supplementation 
ceased. Treatment with Hydroxocobalamin showed a more modest short term increase in serum 
Vitamin B12 level but had a more consistent long term profile. It may be suggested that a 
combination of both treatment options be considered; an initial three month treatment period of 
sublingual supplementation to build up serum levels followed by maintenance of corrected levels 
with periodic Hydroxocobalamin injections.  
Results from neuropathy screening suggest that which has been previous suggested; 
decreased Vitamin B12 status in metformin treated patients is not based on levels of physiologically 
functional Vitamin B12 and is therefore not clinically detrimental. While the number of patients 
exhibiting neuropathic symptoms was low, it can be suggested that this was due to the sample size 
of patients assessed, and as no control group was considered it is difficult to rule out the absence of 
neuropathy caused by decreased Vitamin B12 levels associated with metformin treatment. 
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6.3 – An Alternate Hypothesis 
 
6.3.1 – Asymptomatic deficiency 
Of concern is the low number of published findings that link the decrease of serum Vitamin B12 
level seen in metformin treated patients to direct physiological impairment of Vitamin B12 
functionality. As mentioned before recent papers (de Groot-Kamphuis et al., 2013; Obeid et al., 
2013) have suggested that the lowered status of Vitamin B12 as a result of metformin treatment is 
not a true deficiency and thus explain the apparent absence of the well documented symptoms of 
Vitamin B12 deficiency through other routes of pathogenesis. These two papers both put forth 
evidence that whilst the classic lowered serum levels are still seen in the test populations, 
intracellular and functional Vitamin B12 levels were not altered after metformin exposure. 
Investigation is needed to explain why the traditionally low serum Vitamin B12 level which would 
usually indicate a deficient state of cobalamin are being found to be asymptomatic.  
  
 6.3.2 – Displacement vs. malabsorption 
A potential mechanism for this phenomena can be drawn from results in a study mentioned 
previously in which a population of rats were intravenously administered a 3 week regimen of 
metformin treatment (Greibe, Miller, et al., 2013). The study mimicked previous reductions in 
plasma Vitamin B12, however showed that rather than a decreased absorption of cobalamin, the 
results suggest a displacement of cobalamin into the liver of the treated rats. Results show 36% 
higher liver content in the liver of the metformin treated population compared to the saline, 
control, population. This was coupled with a 34% decrease in cobalamin found in the kidney of the 
cases. Total cobalamin detected in the rats was comparable between the two populations and 
suggested that there was no presence of malabsorption from dietary Vitamin B12 sources. This 
mechanism of displacement would explain the state in which a patient being treated with metformin 
has a decreased serum level of Vitamin B12 but no markers of traditional deficiency. As the liver is 
known to be the main storage organ for Vitamin B12 the increased uptake would allow continual 
physiological functionality of the vitamin.  
A key weakness in this study however is the mode of delivery of metformin into the body of 
the rats. As the drug is administered subcutaneously it avoids the potential site of interaction in the 
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gut where Vitamin B12 is proposed to be interfered with. During cobalamin absorption the vitamin 
binds to cubulin receptors which are required for the calcium dependent channelling of the 
molecule into the ileum. However it is believed that competitive metformin binding to this B12-
cubulin complex leads to membrane potential alterations and repulsion of calcium ions. As the 
channel is calcium instigated the interaction leads to malabsorption (Gilligan, 2002). This 
interaction is supported by results from calcium supplementation which is seen to reverse the 
malabsorption in treated patients (Bauman et al., 2000) by reactivating the calcium dependent 
channels. However the results from the Greibe et al paper may still hold true via oral administration 
of metformin but have a less severe increase on preferential absorption by the liver due to a tandem 
malabsorption affect which has been commonly suggested. This would explain the presence of 
correlations between both drug dosage and duration of treatment as seen in this study and previous 
literature whilst explaining the continual functionality of Vitamin B12. Current assessment of 
Vitamin B12 levels are through either serum levels or metabolite levels. As there have been no 
studies found which have assessed the possibility of increased internal Vitamin B12 storage in the 
liver of patients being treated with metformin the mechanism could be a plausible reason for 
absence of symptoms in treated patients.  
This theory is supported by evidence put forth which suggested an increased ability to 
absorb circulating serum Vitamin B12 in patients treated with metformin (Obeid et al., 2013). This 
theory claims that lowered levels of serum Vitamin B12 in patients being treated with metformin is 
indicative of an increased intracellular level of B12, this is supported by an absence in changes in 
physiological functions of Vitamin B12 (Greibe, Trolle, Bor, Lauszus, & Nexo, 2013). Further 
evidence of this is noted in a study which highlights the absence of typical Vitamin B12 deficiency 
symptoms in patients with metformin induced deficiency (de Groot-Kamphuis et al., 2013). A 
study on the effect of metformin on cobalamin status of women with polycystic ovary syndrome 
further supported this claiming that while serum Vitamin B12 level dropped significantly with 
introduction of metformin treatment, measures of physiological cobalamin (holotranscobalamin) 
were not altered (Greibe, Trolle, et al., 2013). It may be suggested that a decrease in serum 
Vitamin B12 in type 2 diabetic patients being treated with metformin is due to increased uptake of 
TCII-B12 complexes for both cellular use and organ storage, therefore not leading to a deficient 
B12 state but rather a lower circulating measured Vitamin B12 concentration.  
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The mechanism of interaction that would lead metformin causing such a displacement effect 
on Vitamin B12 is not elucidated to in the Greibe et al paper. A potential mechanism may involve an 
increase in affinity to haptocorrin binding by cobalamin. As the protein has corresponding cell 
surface receptors located only on reticuloendothelial storage cells(Herbert, Fong, Gulle, & Stopler, 
1990) this may lead to increase in Vitamin B12 deposit in the liver. As the mechanism of metformin 
function on inhibition of gluconeogenesis is believed to primarily liver based there may be a direct 
influence on liver uptake of circulating cobalamin after metformin exposure. In order to understand 
such a mechanism further study must be conducted into the possibility of Vitamin B12 storage in 
the liver as a cause of lowered serum Vitamin B12. Furthermore, assessment of serum Vitamin B12 
level have been shown to be inadequate in their own for the diagnosis of Vitamin B12 deficiency and 
evidence has been seen that such information be interpreted with caution.  The assessment of 
patients in this study was based on serum levels alone primarily because of funding restrictions, but 
also as this is the measure analysed routinely in primary care.  
  
6.3.3 – Evidence from study results 
Increased liver uptake of cobalamin also leads to a further understanding of the overall shape of 
serum Vitamin B12 in patients who were treated with the Hydroxocobalamin injection. The 
increase at the 3 month time point was followed by a decrease of only 14.3% over the following 3 
months during which time there was no repeated treatment of patients. This decrease had a mean 
value of 24.75 pmol/L over the 3 month observation period (Table 5.4.2) and may be attributed to 
the natural utilization of Vitamin B12 by the liver as it secretes the vitamin into bile in an 
enterohepatic cycle, in which up to 60% is not reabsorbed (Gherasim et al., 2013; Kanazawa & 
Herbert, 1983). Longer observation of patients following the administration of Hydroxocobalamin 
would allow a higher understanding of the residual effect of Hydroxocobalamin absorption and 
distribution throughout the body.   
 
 
6.3.3 – Diagnosis of deficiency 
There are contradicting beliefs on the relevance of serum Vitamin B12 level in patients with Type 2 
Diabetes who are being treated with metformin. Obeid et al suggest that the serum level of the 
vitamin itself is not sufficient enough in assessing the bioavailability and chemical activity of Vitamin 
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B12 as the lowered serum level of the vitamin does not necessarily reflect any functional 
disadvantage in the patient (M. R. Turner & Talbot, 2009). The study suggests that only through 
assessment of Vitamin B12 metabolites (holotranscobalamin and methylmalonic acid) and 
intracellular levels can a full understanding and evaluation of metformin influence be 
achieved(Obeid et al., 2013). Strong evidence is given to show higher methylation indices in 
patients treated with metformin which would indicate higher level of Vitamin B12 functionality in 
these patients. This theory is supported by work by de Groot-Kamphuis et al which highlights that 
although there is an observed Vitamin B12 deficiency (measured only through serum level 
assessment) in patients treated with metformin, there are no clinical consequences of such 
deficiency in the patient population(de Groot-Kamphuis et al., 2013).  
 
Conversely, studies published recently have completely contradictory results to the above 
mentioned. Wile et al. exhibited that metformin treatment for a period of longer than three months 
was associated with decreased serum Vitamin B12 level (as seen in many studies), but also in higher 
homocysteine and methylmalonic acid (MMA) levels, which would suggest an inhibited Vitamin 
B12 functionality (Wile & Toth, 2010). These observations were linked to clinical consequences 
with increased neuropathy scores. However it is key to note that the recruitment for said study was 
based on a requirement of existing peripheral neuropathy as well as metformin treatment. This 
selection criterion may lead to external factors contributing towards the presence of altered 
biochemical markers as the clinical significance of Vitamin B12 deficiency was a selection criteria as 
opposed to a measured outcome.  
A further study conducted by Sato et al (Sato, Ouchi, Funase, Yatnauchi, & Aizawa, 2013) 
attempts to draw a similar association between metformin treatment and a change in the 
biochemical markers of Vitamin B12 functionality. Once again there was an associated decrease in 
serum Vitamin B12 in the metformin treated patients compared to a non-metformin treated 
population. This association continued with altered ratios of homocysteine (HC):B12; however 
there was no significant correlation found directly between metformin treatment and increased 
homocysteine levels. This suggests that while the mentioned ratio of HC: B12 changed, this result 
was due to the lowering of serum Vitamin B12 and not a significant increase in homocysteine. The 
study continues to draw significant correlations between the markers of HC and impaired 
physiological functions of retinopathy and renal function (eGFR) however fails to relate the HC 
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increase exclusively to metformin treatment. Furthermore the study relies on a metformin treated 
population which is comprised of patients with a significantly higher mean body mass index (BMI), 
26.1 ± 4.2 vs. 24.3 ± 3.0 (p = 0.02), than the non-metformin population. The factor of BMI has 
been shown to increase levels of HC independent of treatment (Park & Georgiades, 2013; Sanlier & 
Yabanci, 2007), and therefore any physiological differences between the two populations may be as 
a result of this association.  
In the presence of true Vitamin B12 deficiency the risk of developing hyperhomocystemia 
has been documented in populations with type 2 diabetes and without subdivision of treatment with 
metformin (Mahalle, Garg, Kulkarni, & Naik, 2013). In these particular studies the drop in serum 
Vitamin B12 status was attributed to both the presence of a diabetes state and the high prevalence of 
Vitamin B12 deficiency in the national populations. Dietary Vitamin B12 deficiency has been a 
documented problem in India due to vegetarianism, and leads to development of 
hyperhomocystemia.  
Singh, A et al exhibited differences in neuropathy which were attributed to impaired serum 
Vitamin B12 level in a metformin treated population compared to a non-metformin treated 
population (Singh, Kumar, Karmakar, & Jha, 2013). The use of the Toronto Clinical Neuropathy 
Screening System allowed for assessment of neuropathy in the study populations. While there were 
significant results found between the groups, these were limited to a slight increase in number of 
patients expressing mild neuropathy in the metformin group. There was no significant difference in 
moderate or severe neuropathy findings between the populations.  
 
 
 6.3.4 – Potential implications 
Through the observation of both confounding prevalence rates and the potential mechanism of 
Vitamin B12 displacement and not malabsorption it is proposed that metformin may not have 
clinical significance on Vitamin B12 functionality. It has been shown that while there is an increased 
prevalence of decreased serum Vitamin B12 level in metformin treated patients, this increase may 
not be attributed solely to metformin use but rather a combination of factors. The influences of age 
and nutritional intake have both shown much stronger correlations with Vitamin B12 status. 
Furthermore evidence has been shown and discussed which suggests that a decrease in serum 
Vitamin B12 that arises as a result of metformin treatment may not be clinically detrimental owing 
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to the absence of both symptomatic expression and biochemical functionality impairment in patients 
showing decreased serum levels. It has been proposed that while there may be a level of 
malabsorption of Vitamin B12 due to metformin interaction, the change in serum levels may also be 
caused by a displacement of Vitamin B12 into storage sites where it remains functional.  
 Further studies should aim to address this apparent displacement model and assess the 
functionality of Vitamin B12 in patients expressing decreased serum levels in order to ascertain if 
there is physiological indication of deficiency. This could avoid the potentially unnecessary 
treatment of many patients who have apparent Vitamin B12 deficiency, but normally functioning 
levels of the vitamin. This may also alleviate the need for monitoring of Vitamin B12 levels in those 
taking metformin and would reduce the burden both personally and financially on patients and the 
health system. 
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8.0 – Appendices 
 
 Appendix A – Serum Vitamin B12 assay protocol 
 
IMMUNOASSAY METHODS MANUAL – Vitamin B12 
Appendix A   
Issued: 18/04/13 Supersedes version date: 26/07/11 Section 1 of 3 
 
Issuing Authority: HOD Biochemistry, Aotea Pathology Ltd 
  
Vitamin B12 3.2.doc 
VITAMIN B12 
Principle
Competitive electrochemiluminescence immunoassay 
Specimen Requirements1 
 
Serum (SST) (BIOHAZARD) √ 
Plasma  
Na Heparin or  K3-EDTA plasma (Preferably fasting) 
√ 
Stability 
2 – 8oC   
 
48 hours  
 
-20oC (Protected from light) 
 
2 months 
 
 Samples must be free from cells and particulate matter. 
 Freeze only once and mix thawed samples prior to analysis. 
 Protect serum from light  
 Do not use heat-inactivated samples. 
 Patient samples, calibrators and controls must be brought to room temperature (20-25oC) 
before analysis. 
 Azide–stablilised samples, calibrators and controls are unsuitable for analysis. 
 
Reagent Handling 
Reagents in kit are ready to use.  Store kit upright in order to ensure complete availability of  
microparticles during automatic mixing prior to use. Open bottle caps manually before use. Allow 
cooled reagents to equilibrate to room temperature before placing onto reagent carousel.  Avoid 
the formation of foam.  
 
WARNING:  
Pre-Treatment 2 reagent (grey cap) contains Sodium Hydroxide (CORROSIVE), and Sodium 
Cyanide (TOXIC). Refer to Section 1: Safety. 
Performance Specifications1 
 
Sensitivity Analytical:   22 pmol/L 
Functional:  Not stated 
Measuring Range:   22 – 1476 pmol/L 
 
Dilution Protocols 
Specimen pre-dilution is not required (see Results Management) 
 
Analytical Specificity1 
The following cross-reactivity was found: 
Cobinamide dicyanide  200ng/mL  0.024% 
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Interferences and Limitations1 
 
Interferent Level of interferent below 
which there is < 10% 
interference 
Haemoglobin  <10 g/L 
Bilirubin  <1112 µmol/L 
Lipaemia  <15 g/L 
Biotin  <205 nmol/L 
 
Other: 
 
 In patients receiving therapy with high biotin doses (i.e. >5mg/day) no sample should be taken 
until 8 hours after the last biotin administration. 
 In rare cases, interference due to extremely high titres of antibodies to analyte-specific 
antibodies, streptavidin or ruthenium can occur. 
 Samples with extremely high total protein concentrations (e.g. patients suffering from 
Waldenstrom’s macroglobulinaemia) are not suitable for use in this assay, since they may lead 
to the formation of protein gel in the assay cup.  The critical protein concentration is dependant 
upon the individual sample composition 
 
Reference Interval2 
 
 Vitamin B12: Unisex 130 – 830 pmol/L. 
 
Results Management 
 Results <44 pmol/L  - autp report using <B12. 
 Results >1475 pmol/L – auto report >B12. 
 
B12 results less than 250 pmol/L are held on verification screen for manual release. 
 
Confirm QC results are satisfactory (for each reagent pack in use) before releasing results.  
 
If QC results are within specification, release results ≥ 90 pmol/L. 
  
If result is < 90 pmol/L -  check previous result(s) where available. If previously low, then release 
current result. 
 
If this is the first low B12 result for a patient - check MCV. If MCV ≥98, release result.  Otherwise 
repeat B12 assay. If repeat result is within 20 pmol/L, add comment `conf`` to the report. 
Interpretation 
Nutritional and macrocytic anaemias can be caused by a deficiency of Vitamin B12.  This 
deficiency can result from diets devoid of meat and bacterial products, from alcoholism or from 
structural/functional damage to digestive of absorptive processes (forms of pernicious anaemia).  
Malabsorption is the major cause of deficiency, through pancreatic deficiency, gastric atrophy or 
gastrectomy, intestinal damage, loss of intestinal Vitamin B12 binding protein (intrinsic factor), 
production of autoantibodies directed against intrinsic factor, or related causes.  Vitamin B12 is 
necessary for normal metabolism, DNA synthesis and red blood cell regeneration.  Untreated 
IMMUNOASSAY METHODS MANUAL – Vitamin B12 
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Issuing Authority: HOD Biochemistry, Aotea Pathology Ltd 
  
deficiencies will lead to megaloblastic anaemia and irreversible central nervous system 
degeneration. 
 
Normal absorption of B12 requires a non-vegetarian dietary source, a normal stomach to produce 
intrinsic factor, and a normal terminal ileum to absorb the B12/IF complex. A healthy person with 
replete body stores has enough B12 to last 3-6 years if no more is ingested. 
 
Low B12 levels causes include: 
 vegetarian diet  
 drugs - oral contraceptives, metformin, methotrexate, colchicine, slow K, anticonvulsants, 
cimetidine, triamterene  
 pregnancy - B12 levels are often low without tissue deficiency  
 low B12 binding protein, transcobalamin I, which can be measured, but the expense is 
seldom warranted  
 pernicious anaemia  
 Intrinsic factor/parietal cell antibodies. 
 malabsorption  
 inflammatory bowel disease: Crohn's disease, or ulcerative colitis in the terminal ileum  
 previous gastrectomy or ileectomy  
 primary folate deficiency  
 Diphyllobothrium fish tapeworm infestation (loss of ingested B12) 
 
Further investigation and treatment of low B12 
 
If haematological abnormalities are present - raised MCV, anaemia, neutropenia, 
thrombocytopenia, oval macrocytes and hypersegmented neutrophils in the blood film - the 
underlying cause must be identified 
If there are no haematological abnormalities and the patient seems healthy, there is less urgency. 
The level may be normal for that person or it may indicate early deficiency. It is a matter of clinical 
judgement and patient choice whether to investigate further at once; or follow-up in 6. The elderly 
often have low B12 and folate levels and may benefit from supplements. 
 
Elevated B12 levels include: 
 oral or parenteral vitamin B12 supplement  
 haematological disorders: myeloproliferative disorders, leukaemias, high white cell counts  
 liver disease , chronic renal failure, severe CHF 
References 
 
1. Roche package insert 04761707001 
2. Aotea Pathology: Data on file 
 
 
 146 
Appendix B – Baseline Questionnaire for patients in randomised 
control trial 
Metformin and Vitamin B12 Study Baseline Questionnaire    
 
 
Baseline Questionnaire Version# 1: 11.06.09   1 
Metformin and Vitamin B12 Study 
 
Study ID:        NHI:      
Date:   
Surname:……………………………….   First Name: …………………………. 
Preferred name:…………………………Title: Mr / Mrs / Miss / Ms (delete what does not apply)   
Date of birth:                              
Sex :    
Full Address: …………………………………………………………………………. 
………………………………………………………………………………………… 
……………………………………………………Postcode……………………….. 
Phone:   Home …………………………………………. 
  Work …………………………………………    
  Mobile …………………………………………. 
E mail address:  ……………………………………………. 
Ethnicity:  Tick all that apply 
 
   New Zealand European  
   Maori     
   Samoan    
   Cook Island Maori   
   Tongan    
   Niuean     
   Chinese    
   Indian     
   Other    __________________ 
 
Name of General Practitioner: ……………………………….  
Medical Centre: 
…………………………………………………………………
…………………………………………………………………
…………………………………Postcode ……………………. 
 
 
What year were you diagnosed with diabetes? …………………….. 
Metformin and Vitamin B12 Study Baseline Questionnaire    
 
 
Baseline Questionnaire Version# 1: 11.06.09   2 
 
  
What year was metformin started? …………………………… 
 
Exclusion checklist: (If “Yes” ticked the person is ineligible) Yes     No       
  
Existing treatment for B12 deficiency     
Folate deficiency or related anaemia     
Pregnancy or lactation          
Cobalamin allergy           
Other reasons why taking part would be practically difficult     
       
Relevant Medical Conditions:                                      Yes     No 
Gastroparesis             
Inflammatory bowel disease                         
Thyroid disease             
……………………………………………………………………………….
………………………………………………………………………………. 
………………………………………………………………………………. 
………………………………………………………………………………. 
 
Current medications and doses:   
 
Diabetes treatment:  
……………………………………………………………………………. 
……………………………………………………………………………. 
……………………………………………………………………………. 
Other prescribed treatment: 
………………………………. …………………………………………... 
……………………………………………………………………………. 
……………………………………………………………………………. 
……………………………………………………………………………. 
Metformin and Vitamin B12 Study Baseline Questionnaire    
 
 
Baseline Questionnaire Version# 1: 11.06.09   3 
 
Are you currently taking antibiotics? ………………………. 
 
(if so, must take the vitamin B12 tablets at a different time of day to the antibiotic) 
 
Are you currently taking any of the following medications: Y N 
 
Oral contraceptives          
Chloramphenicol         
Colchichine         
Ranitidine (Zantac)         
Phenobarbital         
Omeprazole (Losec) /pantoprazole (somac)     
 
(these medications can also lower B12 status) 
 
Have you experienced ongoing unusual fatigue or tiredness 
over the last three months?        
 
 
Do you drink alcohol?             
 
If yes – how many units per week: …………………………… 
 
Do you smoke?         
 
If yes – how many packs per week …………………………… 
 
 
 
Study Forms: 
 
Michigan neuropathy screening questionnaire         
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 Appendix C – Michigan Neuropathy Screening Instrument 
 
 MNSI, © University of Michigan, 2000 
 
 
Patient Version 
 
 
MICHIGAN NEUROPATHY SCREENING INSTRUMENT 
 
 
A. History (To be completed by the person with diabetes) 
 
 Please take a few minutes to answer the following questions about the feeling in your legs 
and feet.  Check yes or no based on how you usually feel.  Thank you. 
 
 1. Are you legs and/or feet numb?   Yes   No 
 2. Do you ever have any burning pain in your legs and/or feet?   Yes   No 
 3. Are your feet too sensitive to touch?   Yes   No 
 4. Do you get muscle cramps in your legs and/or feet?   Yes   No
 5. Do you ever have any prickling feelings in your legs or feet?   Yes   No 
 6. Does it hurt when the bed covers touch your skin?   Yes   No 
 7. When you get into the tub or shower, are you able to tell the  
  hot water from the cold water?   Yes   No 
 8. Have you ever had an open sore on your foot?   Yes   No 
 9. Has your doctor ever told you that you have diabetic neuropathy?   Yes   No 
 10. Do you feel weak all over most of the time?   Yes   No 
 11. Are your symptoms worse at night?   Yes   No 
 12. Do your legs hurt when you walk?   Yes   No 
 13. Are you able to sense your feet when you walk?   Yes   No 
 14. Is the skin on your feet so dry that it cracks open?   Yes   No 
 15. Have you ever had an amputation?   Yes   No 
 
 Total:    
       
 
 
 
 
 MNSI, © University of Michigan, 2000 
 
 
 
 
 
 
MICHIGAN NEUROPATHY SCREENING INSTRUMENT 
 
B. Physical Assessment (To be completed by health professional) 
 
 1. Appearance of Feet 
   Right Left 
  a. Normal   0 Yes  1 No Normal   0 Yes  1 No 
  b. If no, check all that apply: If no, check all that apply: 
 
  Deformities    Deformities   
  Dry skin, callus   Dry skin, callus   
  Infection     Infection    
  Fissure     Fissure    
  Other     Other    
 specify:    specify:     
    Right Left 
    Absent  Present Absent  Present 
2. Ulceration  0   1  0   1  
 
 
      Present/  Present/ 
    Present Reinforcement Absent Present Reinforcement Absent 
3. Ankle Reflexes   0    0.5   1   0   0.5   1  
 
 
    Present Decreased Absent Present Decreased Absent 
4. Vibration   0    0.5   1   0   0.5   1  
 perception at 
 great toe 
 
5. Monofilament Normal  Reduced        Absent                           Normal           Reduced          Absent 
        0      0.5  1  0                      0.5   1 
 
 
 
 
Signature:   Total Score   /10 Points 
  
 
How to Use the Michigan Neuropathy Screening Instrument 
 
 
History 
 
The history questionnaire is self-administered by the patient.  Responses are added to 
obtain the total score.  Responses of “yes” to items 1-3, 5-6, 8-9, 11-12, 14-15 are each 
counted as one point.  A “no” response on items 7 and 13 counts as 1 point.  Item #4 is a 
measure of impaired circulation and item #10 is a measure of general aesthenia and are 
not included in scoring.  To decrease the potential for bias, all scoring information has 
been eliminated from the patient version.  
 
Physical Assessment 
 
For all assessments, the foot should be warm (>30°C). 
 
Foot Inspection:  The feet are inspected for evidence of excessively dry skin, callous 
formation, fissures, frank ulceration or deformities.  Deformities include flat feet, 
hammer toes, overlapping toes, halux valgus, joint subluxation, prominent metatarsal 
heads, medial convexity (Charcot foot) and amputation.  
 
Vibration Sensation:  Vibration sensation should be performed with the great toe 
unsupported.  Vibration sensation will be tested bilaterally using a 128 Hz tuning fork 
placed over the dorsum of the great toe on the boney prominence of the DIP joint.  
Patients, whose eyes are closed, will be asked to indicate when they can no longer sense 
the vibration from the vibrating tuning fork.   
 
In general, the examiner should be able to feel vibration from the hand-held tuning fork 
for 5 seconds longer on his distal forefinger than a normal subject can at the great toe 
(e.g. examiner’s DIP joint of the first finger versus patient’s toe).  If the examiner feels 
vibration for 10 or more seconds on his or her finger, then vibration is considered 
decreased.  A trial should be given when the tuning fork is not vibrating to be certain that 
the patient is responding to vibration and not pressure or some other clue.  Vibration is 
scored as 1) present if the examiner senses the vibration on his or her finger for < 10 
seconds, 2) reduced if sensed for ≥ 10 or 3) absent (no vibration detection.) 
 
Muscle Stretch Reflexes: The ankle reflexes will be examined using an appropriate reflex 
hammer (e.g. Trommer or Queen square).  The ankle reflexes should be elicited in the 
sitting position with the foot dependent and the patient relaxed.  For the reflex, the foot 
should be passively positioned and the foot dorsiflexed slightly to obtain optimal stretch 
of the muscle.  The Achilles tendon should be percussed directly.  If the reflex is 
obtained, it is graded as present.  If the reflex is absent, the patient is asked to perform the 
Jendrassic maneuver (i.e., hooking the fingers together and pulling).  Reflexes elicited 
with the Jendrassic maneuver alone are designated “present with reinforcement.”  If the 
  
reflex is absent, even in the face of the Jendrassic maneuver, the reflex is considered 
absent.   
 
Monofilament Testing:  For this examination, it is important that the patient’s foot be 
supported (i.e., allow the sole of the foot to rest on a flat, warm surface).  The filament 
should initially be prestressed (4-6 perpendicular applications to the dorsum of the 
examiner’s first finger).  The filament is then applied to the dorsum of the great toe 
midway between the nail fold and the DIP joint.  Do not hold the toe directly.  The 
filament is applied perpendicularly and briefly, (<1 second) with an even pressure.  When 
the filament bends, the force of 10 grams has been applied.  The patient, whose eyes are 
closed, is asked to respond yes if he/she feels the filament.   Eight correct responses out 
of 10 applications is considered normal: one to seven correct responses indicates reduced 
sensation and no correct answers translates into absent sensation.  
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 Appendix D – Otago School of Medicine Food Questionnaire 
Study Number!

Food? 
Questionnaire 1 
 





Different eating patterns have an effect on people’s health.  To help us 
understand these eating patterns we would like you to think about all 
the foods you have had over the last year and answer the following 
questions about the foods you usually eat.  This food questionnaire 
measures how often, on average, you have eaten a specified amount of 
food over the past 12 months.
 
 
 
 


If you  have  any  queries  regarding  this  questionnaire please  contact: 
FFQ1 v3 Feb 12 
YOUR DIET LAST YEAR 
For each food there is an amount shown, either "one serving”, or an example of a 
serving such as "a slice" or "a teaspoon".  Please put a tick (✔) in the box to indicate 
how often, on average, you have eaten a specified amount of food over the last 12 
months. Answer each question as best you can. Estimate if you are not sure. A guess is 
better than no answer! When you are finished the questionnaire please check every page 
to see if you have missed any questions. Please complete the questionnaire using a blue 
or black pen. The rest of this page shows examples of how to fill in the questionnaire. 
These questions are all about the food you have eaten over the last year. 
 
Example 1: 
 
 
When asked how often I eat “Apples” I usually have 3 apples every week.  The 
serving size is one piece of fruit.  Therefore I have 3 servings per week and should 
place a tick in the “2-4 per week” box.
 
When asked how often I eat “White bread (1 slice/roll)” I usually have 3 slices of bread 
and 2 rolls every week.  The serving size is one slice or roll.  Therefore I have 5 servings 
per week and should place a tick in the “5-6 per week” box.
Example 2: 
 
Never or less than 
once per m
onth
1-3 per m
onth

Once per week

2-4 per week

5-6 per week

1 every day

2 or m
ore every day

Apples (1 fruit)  
Never or less than 
once per m
onth
1-3 per m
onth

Once per week

2-4 per week

5-6 per week

1 every day

2 or m
ore every day

White bread (1 slice/roll) 
✔
✔
Never or less than 
once per m
onth
1-3 per m
onth

Once per week

2-4 per week

5-6 per week

1 every day

2 or m
ore every day

DAIRY PRODUCTS AND EGGS
Cream or sour cream (1 tablespoon)
Low fat, low sugar yoghurt (1 small pottle) 
e.g. Delite, Fresh ‘n’ Fruity lite
Please check that you have put a tick (✔) on EVERY line 
FOOD AND AMOUNTS AVERAGE USE IN THE LAST TWELVE MONTHS
Full fat or Greek yoghurt (1 small pottle) 
e.g. Cyclops, Puhoi Valley
Dairy desserts (1 small pottle) 
e.g. chocolate mousse
Eggs as boiled, fried, scrambled etc 
(1 egg)
Cheese (1 matchbox size) 
e.g. cheddar, mild, brie, edam 
Quiche (1 slice)
Cottage/feta Cheese (2 tablespoons) 
e.g. Tararua, Country Goodness
Low fat mayonnaise (1 tablespoon) 
e.g. ETA Lite n’ Free 
French dressing (1 tablespoon) 
Full fat mayonnaise (1 tablespoon) 
e.g. Best Foods real mayonnaise, Heinz
Salad dressing (1 tablespoon)  e.g. Pams 
creamy salad dressing, coleslaw dressing
Low fat yoghurt, fromage frais (1 small pottle) 
e.g. Fresh ‘n’ Fruity, Meadow Fresh
Never or less than 
once per m
onth
1-3 per m
onth

Once per week

2-4 per week

5-6 per week

1 every day

2 or m
ore every day
The following list refers to DAIRY 
PRODUCTS AND FATS that you 
put on bread or cooked vegetables
FOOD AND AMOUNTS AVERAGE USE IN THE LAST TWELVE MONTHS
Butter (1 teaspoon)
Polyunsaturated margarine (1 teaspoon) 
e.g. Flora, Gold ‘n’ Canola
Olive oil spread (1 teaspoon) 
e.g. Olivio or Olivani
Other margarines (1 teaspoon) 
e.g.  Pams, MeadowLea
Cholesterol lowering fat spreads 
(1 teaspoon) e.g. Pro-active, Logicol
Reduced fat spread (1 teaspoon) 
e.g. Flora ultra lite 

Reduced fat butter (1 teaspoon) 
e.g. Mainland Country soft lite, Tararua 
super soft lite
Please check that you have put a tick (✔) on EVERY line 
Never or less than 
once per m
onth
1-3 per m
onth

Once per week

2-4 per week

5-6 per week

1 every day

2 or m
ore every day

FRUIT
For seasonal fruits marked*, please 
estimate your average consumption 
when these are in season
FOOD AND AMOUNTS AVERAGE USE IN THE LAST TWELVE MONTHS
Pears (1 fruit)
Apples (1 fruit)
Oranges (1 fruit), mandarins (2 fruit)
Grapefruit (half)
Banana (1 fruit)
Grapes (1 handful)
Melon (1 slice)
*Peaches, plums, apricots  (1 fruit)
*Strawberries, raspberries, other berries
 (1 handful)
Kiwifruit (1 fruit)
Tinned fruit (1/2 a cup)
Dried fruit (1 heaped tablespoon) 
e.g. raisins, prunes
Please check that you have put a tick (✔) on EVERY line 
Never or less than 
once per m
onth
1-3 per m
onth

Once per week

2-4 per week

5-6 per week

1 every day

2 or m
ore every day

VEGETABLES
Fresh, frozen or tinned
FOOD AND AMOUNTS AVERAGE USE IN THE LAST TWELVE MONTHS
Watercress/ Puha (handful)
Onions (handful)
Garlic (1 clove)
Bean sprouts (handful)
Green salad, lettuce, cucumber, celery 
(handful)
Mushrooms (handful) 
Capsicum (handful)
Tomatoes (handful)
Sweetcorn (handful)
Beetroot (handful)
Coleslaw (handful)
Avocado (half)
Please check that you have put a tick (✔) on EVERY line 
Carrots (handful)
Never or less than 
once per m
onth
1-3 per m
onth

Once per week

2-4 per week

5-6 per week

1 every day

2 or m
ore every day

VEGETABLES
Fresh, frozen or tinned
FOOD AND AMOUNTS AVERAGE USE IN THE LAST TWELVE MONTHS
Spinach/Silverbeet (handful)
Brussel sprouts (handful) 
Green beans, broad beans, runner beans 
(handful)
Peas (handful)
Cabbage (handful)
Baked beans (handful)
Cauliflower (handful) 
Marrow, courgettes (handful) 
Broccoli (handful)
Parsnips, turnips, swedes (handful)
Leeks (handful)
Pumpkin/Kumara (handful)
Please check that you have put a tick (✔) on EVERY line 
Lentils, chickpea, pulses (handful)
e.g. red kidney bean
Never or less than 
once per m
onth
1-3 per m
onth

Once per week

2-4 per week

5-6 per week

1 every day

2 or m
ore every day

MEAT AND FISH
(half a cup)
FOOD AND AMOUNTS AVERAGE USE IN THE LAST TWELVE MONTHS
Please check that you have put a tick (✔) on EVERY line 
Beef: roast, steak, mince, casserole or stew 
Beef burgers
Pork: roast, steak, mince, chops, 
casserole or stew
Chicken or other poultry: roast, steak, 
chops, mince, casserole or stew
Sausages
Bacon
Corned beef, spam, luncheon meats
Ham, cured meats, salami, chorizo
Savoury pies 
e.g. meat pie, pork pie, pastries, steak 
and kidney pie, sausage roll
Fried fish in batter (one piece) as in fish 
and chips 
Liver, liver pate, liver sausage  
Fish fingers, fish cakes and crumbed fish 
e.g. Birdseye oven bake
White fish, fresh or frozen 
e.g. hoki, cod, sole, gurnard, tarakihi 
Other fish 
e.g. tuna, mackerel, salmon, sardines
Shellfish 
e.g. crab, prawns, mussels, oysters
Lamb: roast, steak, chops, mince, 
casserole or stew
Meat substitutes e.g. tofu, soymeat, 
textured vegetable protein, vegeburger 
Never or less than 
once per m
onth
1-3 per m
onth

Once per week

2-4 per week

5-6 per week

1 every day

2 or m
ore every day

BREAD AND SAVOURY BISCUITS
White bread (1 slice/roll)
Wholemeal bread (1 slice/roll)
Wholegrain bread (1 slice/roll) 
Cream crackers, savoury biscuits (1 biscuit) 
e.g. Huntley and Palmers
Crispbread, rice crackers (1 biscuit)
e.g. Ryvita, Cruskits, Vitawheat
Naan, poppadoms, flour tortillas (1 piece)
FOOD AND AMOUNTS AVERAGE USE IN THE LAST TWELVE MONTHS
Vegetable soup (bowl)
Meat soups (includes meat and vegetable 
soups) (bowl) 
Tomato sauce (1 tablespoon)
Sauces (1 tablespoon)
e.g. white sauce, cheese sauce, gravy
Pickles, chutneys (1 tablespoon) 
Marmite, vegemite (1 teaspoon)
SOUPS, SAUCES, AND SPREADS
Jam, marmalade, honey (1 tablespoon) 
Peanut butter (1 teaspoon)
Please check that you have put a tick (✔) on EVERY line 
Never or less than 
once per m
onth
1-3 per m
onth

Once per week

2-4 per week

5-6 per week

1 every day

2 or m
ore every day

SWEETS AND SNACKS     
FOOD AND AMOUNTS AVERAGE USE IN THE LAST TWELVE MONTHS
Muffin, slices, pastries (one), brownie
e.g. scones, croissants, doughnuts
Fruit pies, tarts, crumble (one cup)
Cakes (one cup) e.g. chocolate, banana, 
carrot, fruit, sponge
Plain sweet biscuits (two) 
e.g. Nice, Gingernuts
Chocolate sweet biscuits (two) 
e.g. Tim Tams, Toffee Pops.  
Ice cream (one cup)
Please check that you have put a tick (✔) on EVERY line 
Reduced fat biscuits (two) 
e.g. Weight Watchers
Milk puddings (one cup) 
e.g. rice custard, trifle 
Muesli bars, cereal bars (one)
White or milk chocolates, single or 
squares (one)
Dark chocolates, single or squares (one)
Chocolate snack bars (one) 
e.g. Mars, Crunchie
Lollies, toffees, mints (small packet)
Sugar added to tea, coffee, cereal 
(1 teaspoon) 
Nuts (1 handful)
e.g. Brazil, walnuts, peanuts, cashews
Chips, packet snacks (1 small packet)
e.g. Corn chips, cheezels
Seeds (1 tablespoon)
e.g. Sunflower, pumpkin 
Never or less than 
once per m
onth
1-3 per m
onth

Once per week

2 -4 per week

5-6 per week

1 every day

2 or m
ore every day

CEREAL
(One bowl)
Toasted muesli 
Porridge, oats  
Sugar topped cereals e.g. Cocopops, 
Crunchy Nut Cornflakes, Froot Loops
Breakfast cereals 
e.g. Cornflakes, Ricies, Special K, Weetbix
Natural Muesli
High fibre breakfast cereals 
e.g. Bran Flakes, Fibre Plus, All Bran
FOOD AND AMOUNTS AVERAGE USE IN THE LAST TWELVE MONTHS
Potato: Boiled, mashed, instant, baked, 
roasted
POTATOES, RICE AND PASTA
(One cup)
Potato salad
White rice-based dishes
e.g. Stir-fry, curry, savoury sauce
White pasta-based dishes 
e.g. macaroni cheese, spaghetti 
bolognaise, instant noodles
Wholemeal pasta-based dishes 
e.g. macaroni cheese, spaghetti 
bolognaise, instant noodles
Lasagne, moussaka
Pizza (one slice)
French fries, hot chips, wedges, hashbrowns 
Please check that you have put a tick (✔) on EVERY line 
Brown rice-based dishes
e.g. Stir-fry, curry, savoury sauce
Never or less than 
once per m
onth
1-3 per m
onth

Once per week

2-4 per week

5-6 per week

1 every day

2 or m
ore every day

DRINKS
 Black tea (1 cup)
Green Tea (1 cup)
Herb/Fruit Tea (1 cup) e.g. Healtheries Sleep 
Tea, Twinings Peach and Raspberry
Coffee: instant, ground, espresso (1 cup) 
e.g. short black, latte, cappuccino
Milo, Horlicks, Ovaltine (1 cup)
Coffee decaffeinated (1 cup)
Low fat hot chocolate (1 cup) 
e.g. Jarrah, Nestle Double Blend
Cocoa, Hot Chocolate (1 cup) 
e.g. Cadburys, Pams 
Beer, lager or cider (1 standard drink) 
White wine (1 small glass)
Red Wine (1 small glass)
Port, sherry, vermouth, liqueurs 
(1 standard drink)
Spirits (1 nip) e.g. gin, brandy, whisky, vodka 
FOOD AND AMOUNTS AVERAGE USE IN THE LAST TWELVE MONTHS
Standard fizzy soft drinks (1 cup) 
e.g. Coca Cola, lemonade
Fruit juice (100%) (1 cup) 
e.g. orange, apple juice
Smoothies (1 cup)
Standard Cordial (1 cup) e.g. Raro, Refresh
Please check that you have put a tick (✔) on EVERY line 
Diet fizzy soft drinks (1 cup)
e.g. Diet coke, Spite zero
Diet cordial (1 cup)
2. Are there any OTHER foods which you ate more than once a week over the last year?
No              → GO TO question 3              Yes               if yes, please list below






3. Have you drunk milk or milk substitute over the past year? (including in hot drinks)
No            → GO TO question 6              Yes            → GO TO question 4 

4. What type of milk or milk substitute did you most often use over the last year?
    Select one only Full cream (blue top)  Milk powder
 Trim (green top)                   Calci-trim (yellow top) 
 Light milk (light blue top)  Soya 
 other (please specify)
  
5. About how much milk did you drink each day, including milk with tea, coffee, cereals etc?

 Less than half a cup  More than one cup
 Half a cup   More than two cups
 One cup

6. Have you eaten meat in the last year? 
No            → GO TO question 8                  Yes           → GO TO question 7

7. What did you do with the visible fat on your meat? 

Did not eat meat with visible fat  Ate some of the fat 
Trimmed all visible fat and did not  eat  Ate most of the fat

 
 
 
 
YOUR DIET LAST YEAR, continued
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Food      Serving Size             How many times per week? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


8. We would like to summarise what you have told us. During the course of last year, on 
average how many times a week did you eat the following foods?

Food Type              Times/week            Serving size
Vegetables (excluding potatoes             1/2 cup
but including baked beans) 

Salads (e.g. green salad, mesclun)              1 cup  
               


Fruit                 1 medium/2 small


Fish, seafood                                       1/2 cup cooked

Meat, meat products and meat dishes              1/2 cup cooked
(including bacon, ham and chicken)
 


	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  	  	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Thank you for completing this questionnaire!
Please check that you have answered  every 
question.
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Information Sheet 
 
 
The administration of vitamin B12 to people with T2DM on long 
term metformin therapy 
 
Principal investigator- 
Dr Amber Parry Strong, Post-Doctoral Research Fellow, Endocrine, 
Diabetes and Research Centre, Wellington Hospital, Wellington 
 
Co-Investigators 
Dr Jeremy Krebs, Clinical Leader, Endocrine, Diabetes and Research 
Centre, Wellington Hospital, Wellington;  
Sylvan Haeusler, Masters Student, Endocrine, Diabetes and Research 
Centre, Wellington Hospital, Wellington; 
 
 
You are invited to take part in the above study. Your participation is 
entirely voluntary (your choice). You do not have to take part in this 
study, and if you choose not to take part this will not affect any future 
care or treatment. If you do agree to take part in the study, you are free to 
withdraw from the study at any time, without having to give a reason, and 
this will in no way affect your future or continuing health care.  
 
About the study 
 
You have been selected because a blood test taken for the Diabetes Clinic 
at Wellington Hospital showed you have low levels of vitamin B12, and 
you take the diabetes medication Metformin.  
 
The aim of this study is to compare the usual treatment of low vitamin 
B12 (an injection) with vitamin B12 tablets in people taking Metformin. 
 
There are studies showing that taking the diabetes medication Metformin 
can stop people from absorbing vitamin B12 from food, and so over some 
time of taking this medication, vitamin B12 levels can become too low. 
The main symptom of low vitamin B12 levels is tiredness. At the moment 
there is an injection funded to increase vitamin B12 levels again, but we 
would like people to have the choice of an injection or tablets, and we 
need to find out whether the tablets work just as well as the injection. 
This study will help us to know if tablets are a good treatment for people 
with low vitamin B12 levels who take Metformin.  
 
Information Sheet Version 2 21/07/2011 
 2 
 
What will happen during the study 
 
To do this we would like you to come in for one visit to either have the 
injection or collect your tablets, depending on which arm of the study you 
end up in. Whether you get the tablets or the injection will be completely 
random, like the toss of a coin. At your visit we will also ask some 
questions about symptoms you may have been experiencing and check 
for neuropathy. You will then do another blood test three months later to 
see if your B12 levels have increased enough. If they haven’t, you will 
have another course of treatment.  
 
Benefits, Risks and Safety 
 
The major benefit of this study is to further our knowledge of which 
options are effective in treating low vitamin B12 levels in people who 
take Metformin. Your GP will be informed of your participation and 
results of the investigations will be forwarded onto your GP for any 
action. 
 
There is little risk to taking part in the study. We require some of your 
time and the inconvenience of a blood test. Any adverse outcome should 
be covered by ACC compensation provisions. 
 
There will be no direct cost for taking part in the study. We expect to be 
able to cover parking and some transport costs but there is no payment for 
taking part in the study. The vitamin B12 injection or tablets will be 
provided to you for free.  
 
If you require additional information on the trial you can contact Dr 
Jeremy Krebs or Dr Amber Parry strong at the Endocrine, Diabetes and 
Research Centre, Wellington Hospital, Wellington. Phone 04 8062458. 
 
If required an interpreter can be provided. 
If you have any queries regarding your rights as a participant in this 
study, you may wish to contact an independent health and disability 
advocate: 
Free phone : 0800 555 050 
Free fax: 0800 2 SUPPORT (0800 2787 7678) 
Email: advocacy@hdc.org.nz 
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Compensation 
 
In the unlikely event of a physical injury as a result of your participation 
in this study, you may be covered by ACC under the Injury Prevention, 
Rehabilitation, and Compensation Act 2001.  ACC cover is not 
automatic, and your case will need to be assessed by ACC according to 
the provisions of the Injury Prevention, Rehabilitation, and Compensation 
Act 2001.  If your claim is accepted by ACC, you still might not get any 
compensation.  This depends on a number of factors, such as whether you 
are an earner or non-earner.  ACC usually provides only partial 
reimbursement of costs and expenses, and there may be no lump sum 
compensation payable.  There is no cover for mental injury unless it is a 
result of physical injury.  If you have ACC cover, generally this will 
affect your right to sue the investigators. 
 
If you have any questions about ACC, contact your nearest ACC office or 
the investigator. 
 
You are also advised to check whether participation in this study would 
affect any indemnity cover you have or are considering, such as medical 
insurance, life insurance and superannuation. 
 
Confidentiality 
 
All details will be kept in a confidential way as per Capital and Coast 
DHB policy. All subjects will be given a unique identifying code and 
only this will be used as a marker for analysis. No material that could 
personally identify you will be used in any reports on this study will be 
used in any of the final reports. 
 
We expect publication of results in international journals and 
presentations at national or international conferences. Participants are 
able to get copies of reports and presentations if they wish. There will be 
a delay between data collection and publication of results. 
 
This study has received ethical approval from the Central Region Ethics 
Committee, which reviews national and multi regional studies. 
